

1 **Title:**

2 High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T
3 cells that include proliferative memory cells.

4
5 **One Sentence Summary**

6 Individuals with low neutralising antibody titres may be at risk of SARS-CoV-2 re-infection due to a
7 failure to generate a high quality CD4 T cell response specific for receptor binding domain (RBD),
8 including memory CD4 T cells that proliferate in vitro in response to RBD, and which are also
9 therefore an important target for vaccine design.

10

11 **Authors:**

12 Chansavath Phetsouphanh¹, Weng Hua Khoo^{2,3}, Katherine Jackson², Vera Klemm¹, Annett Howe¹,
13 Anupriya Aggarwal¹, Anouschka Akerman¹, Vanessa Milogiannakis¹, Alberto Ospina Stella¹, Romain
14 Rouet², Peter Schofield², Megan L. Faulks², Hannah Law¹, Thidarat Danwilai⁶, Mitchell Starr⁶, C. Mee
15 Ling Munier¹, Daniel Christ², Mandeep Singh^{2,3}, Peter I Croucher², Fabienne Brilot-Turville^{4,5}, Stuart
16 Turville¹, Tri Giang Phan^{2,3}, Gregory J Dore^{1,7}, David Darley⁷, Philip Cunningham⁶, Gail V Matthews¹,
17 ⁷, Anthony D Kelleher^{1,7*}, and John J Zaunders^{6*}

18

19 **Affiliations:**

20 ¹ Kirby Institute, UNSW, Sydney, Australia;

21 ² Garvan Institute of Medical Research, Sydney, Australia;

22 ³ St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia;

23 ⁴ Brain and Mind Centre, Children's Hospital at Westmead, University of Sydney, Australia;

24 ⁵ Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, Australia;

25 ⁶ NSW State Reference Laboratory for HIV, St Vincent's Centre for Applied Medical Research,
26 Australia;

27 ⁷ St Vincent's Hospital Sydney, Australia

28 *These authors contributed equally

29 Correspondence: j.zaunders@amr.org.au

30 Abstract 230 words Text 7602 (Methods: 3099)

31 Figures 8

32 Supplementary Figures 5

33 Supplementary Tables 2

RBD-specific memory CD4 T cells

34
35 Chansavath Phetsouphanh cphetsouphanh@kirby.unsw.edu.au
36 Weng Hua Khoo w.khoo@garvan.org.au
37 Katherine Jackson k.jackson@garvan.org.au
38 Vera Klemm vklemm@kirby.unsw.edu.au
39 Annett Howe annett.howe@hotmail.com
40 Anupriya Aggarwal aaggarwal@kirby.unsw.edu.au
41 Anouschka Akerman aakerman@kirby.unsw.edu.au
42 Vanessa Milogiannakis vmilogiannakis@kirby.unsw.edu.au
43 Alberto Ospina Stella a.ospina.stella@gmail.com
44 Romain Rouet r.rouet@garvan.org.au
45 Peter Schofield p.schofield@garvan.org.au
46 Megan L. Faulks m.faulks@garvan.org.au
47 Hannah Law hlaw@kirby.unsw.edu.au
48 Thidarat Danwilai t.danwilai@amr.org.au
49 Mitchell Starr m.starr@amr.org.au
50 C.Mee Ling Munier cmunier@kirby.unsw.edu.au
51 Daniel Christ d.christ@garvan.org.au
52 Mandeep Singh m.singh@garvan.org.au
53 Peter I Croucher p.croucher@garvan.org.au
54 Fabienne Brilot-Turville fabienne.brilot@sydney.edu.au
55 Stuart Turville sturville@kirby.unsw.edu.au
56 Tri Giang Phan t.phan@garvan.org.au
57 Gregory J Dore gdore@kirby.unsw.edu.au
58 David Darley David.Darley@svha.org.au
59 Philip Cunningham Philip.Cunningham@svha.org.au
60 Gail V Matthews Gmatthews@kirby.unsw.edu.au
61 Anthony D Kelleher akelleher@kirby.unsw.edu.au
62 John J Zaunders j.zaunders@amr.org.au

RBD-specific memory CD4 T cells

63 **ABSTRACT**

64

65 Long-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated
66 immunity, is required in a very large majority of the population in order to reduce ongoing disease
67 burden. We have investigated the association between memory CD4 and CD8 T cells and levels of
68 neutralizing antibodies in convalescent COVID-19 subjects. Higher titres of convalescent neutralizing
69 antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including
70 specific memory cells that proliferated vigorously in vitro. Conversely, up to half of convalescent
71 individuals had low neutralizing antibody titres together with a lack of receptor binding domain (RBD)-
72 specific memory CD4 T cells. These low antibody subjects had other, non-RBD, spike-specific CD4 T
73 cells, but with more of an inhibitory Foxp3+ and CTLA-4+ cell phenotype, rather than the effector T-
74 bet+, cytotoxic granzymes+ and perforin+ cells seen in high antibody subjects. Single cell
75 transcriptomics of antigen-specific CD4+ T cells from high antibody subjects revealed heterogenous
76 RBD-specific CD4+ T cells that comprised central memory, transitional memory and Tregs, as well as
77 cytotoxic clusters containing diverse TCR repertoires, that were absent in individuals with low
78 antibody levels. However, vaccination in low antibody convalescent individuals led to a slight but
79 significant improvement in RBD-specific memory CD4 T cells and increased neutralizing antibody
80 titres. Our results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-
81 region should be prioritized in booster vaccines.

82

83

RBD-specific memory CD4 T cells

84 INTRODUCTION

85

86 The question of the protective efficacy of both convalescent and vaccine induced immunity to SARS-
87 CoV-2 is of global significance. This is highlighted by the multiple waves of infections, with rates of
88 population-wide protection against re-infection of only 50-80% protection during 2020, depending on
89 age (1), or an estimated 60% protection against symptomatic re-infection with the immuno-evasive
90 Omicron variant (2). In order to end the COVID-19 pandemic, a large proportion of the population will
91 need to be immune to the virus (3), or at least, if they become infected, to develop an immune response
92 which minimizes virus shedding, symptoms and onward transmission. Early studies concentrated on
93 serum antibody levels in recovered COVID-19 patients, and in particular neutralizing antibodies, since
94 it is believed that the most effective vaccines to viral infections are associated with the generation of
95 neutralizing antibodies and mimic natural infection (4). The highest titres and affinities of such
96 neutralizing antibodies are generally dependent on CD4 T follicular helper cell (Tfh) interaction with B
97 cells to generate class switching and affinity maturation by somatic hypermutation within germinal
98 centres, in secondary lymphoid organs (5).

99

100 A recent study of the immune response to the mRNA COVID-19 vaccine in SARS-CoV-2 naïve and
101 recovered individuals showed a rapidly induced CD4 T cell response when compared to the gradually
102 developing CD8 T cell response (6). Similarly, when we studied the immune response to vaccinia virus
103 inoculation, highly activated antigen-specific CD4 T cells were often more expanded than
104 corresponding CD8 T cells in blood early in the response (7, 8). Antigen-specific CD4 cytotoxic T
105 lymphocytes (CTL) peaked at day 14, while neutralizing antibodies, and memory CD4 T cells that
106 proliferated in vitro in response to vaccinia antigen appeared later at day 21 (7, 8). The early generation
107 of CD127 (IL-7 receptor alpha chain)-expressing, IL-2-producing, proliferative memory CD4 T cells
108 specific for vaccinia virus is most likely crucial to the long-term protection associated with immunity to
109 smallpox (9). Such T cell proliferation in response to re-exposure to viral antigens is believed to be
110 critical to allow more rapid response to re-infection, after the immune system had returned to
111 homeostasis following contraction of the initial response to the acute infection (reviewed in (10)).
112 Overall, in vitro proliferation of PBMC in response to antigens derived from pathogens is highly
113 correlated with effective immunity (11), due to rapid memory recall response.

114

115 A number of studies early in the pandemic identified SARS-CoV-2 specific CD4 T cells in COVID-19
116 patients (12-16). However, longer term studies showed a consistent average decline of memory CD4 T

RBD-specific memory CD4 T cells

117 cells over time with a decrease until 60 days after the acute phase and maintained over 10 months with
118 a central memory phenotype post 6 month (17, 18). Most of these studies have used upregulation of
119 markers of activation on antigen-specific CD4 T cells, similar to the original OX40 assay (19). In
120 contrast there is very limited data on proliferative memory SARS-CoV-2-specific CD4 T cells (17, 20).

121
122 While CD4 T cell responses are important for antiviral humoral immunity, CD8 T cells are still
123 believed to be important in cell-mediated immunity to respiratory viruses (21). Studies investigating the
124 properties of SARS-CoV-2 reactive CD8 T cells report a high diversity of functional SARS-CoV-2
125 specific CD8 T cells (22-24), with cross-reactivity to seasonal coronavirus antigens (25). This indicates
126 that CD8 T cells could be important in viral clearance in individuals that lack neutralizing antibodies
127 (26, 27), although they often display an exhausted phenotype (22, 23).

128
129 In the current study we systematically studied SARS-CoV-2-specific proliferation of CD4 and CD8 T
130 cells in recovered COVID-19 patients to better define the extent of their long-term memory cells.
131 Importantly, RBD-specific proliferative memory CD4 T cells were closely associated with levels of
132 neutralizing antibodies in recovered patients and in vaccinees. Furthermore, single cell
133 RNAseq/TCRseq was used to study the function of individual SARS-CoV-2 reactive CD4 T cells from
134 subjects with high antibody titres.

135

RBD-specific memory CD4 T cells

136 **RESULTS**

137

138 **Proliferative RBD-specific CD4 T cells correlate with neutralising antibody titres**

139

140 To assess memory CD4 T cell responses following SARS-CoV-2 infection, we screened 25 ADAPT
141 subjects from the first wave (May-October, 2020; Supplementary Table 1) at 3 months post-infection
142 using recombinant SARS-CoV-2 RBD protein, and using influenza lysate as a control antigen. We
143 utilised our CD25/OX40 (19) assay to assess antigen-specificity of CD4 T cells and found overall a
144 13.5-fold higher response to RBD in ADAPT subjects (median 0.46%) at 3 months compared to
145 unexposed controls (n=13; median 0.034%, $p<0.0001$) (Figure 1A&B). However, 7/27 ADAPT
146 subjects were negative (<0.2%) for a response to RBD (Figure 1B). All unexposed controls and
147 ADAPT subjects had positive flu specific responses (medians 1.51% and 1.62%, respectively).

148

149 Having seen initial OX40 responses to RBD, we subsequently used the 7-day PBMC proliferation
150 assay with cell trace violet dye (CTV; Supplementary Figure 1) to confirm the presence of memory
151 CD4 T cells. There was no CD4 T cell proliferation response to RBD (< 1% of CD4 T cells) in PBMC
152 from unexposed controls (n=6), while the ADAPT subjects (n=13) had an overall median proliferation
153 of 11.1%, $p<0.01$. Again the results were heterogeneous with 6 of the 13 ADAPT subjects tested
154 having < 1 % CD4 T cell proliferation in response to RBD, similar to the unexposed controls in this
155 assay (Figure 1C). Proliferation responses to Flu lysate, by both control and patient PBMC, were all
156 positive, similar to the OX40 results, and generally larger than the responses to SARS-CoV-2 RBD
157 (Figure 1C). There was a highly significant positive correlation between CD25+ OX40+ CD4 T cell
158 responses to RBD and CD4 T cell proliferation responses to RBD (pearsons' $\rho=0.89$, $p<0.0001$)
159 (Figure 1D), as we have previously reported for a variety of other recall antigens (19).

160

161 When we compared the levels of anti-spike IgG, measured in the ADAPT subjects' 3-month follow-up
162 serum using the diagnostic DiaSorin Liaison assay, the proliferation of RBD-specific CD4 T cells
163 positively correlated with anti-spike IgG levels ($\rho=0.52$, $p<0.01$; Figure 1E). We also used a flow-
164 based assay (28) to measure spike (Wuhan-1 D614)-specific IgG and IgM in patients' serum samples,
165 which gives scores of 0-3 for each antibody isotype (where 3 is highest). When the IgG and IgM scores
166 were combined, the patients with RBD-specific CD4 T cell responses had significantly higher antibody
167 levels (median score of 5.5) than patients with negative proliferative responses to RBD (median score
168 of 3, $p<0.05$) (Figure 1F).

RBD-specific memory CD4 T cells

169 Finally, live virus neutralization assays were performed with the ADAPT patients' sera, measured as an
170 end-point titre (28). The patients with RBD-specific CD4 T cell responses had significantly higher
171 neutralization titres (NT₅₀, median 256) than patients with negative proliferation results (median 64,
172 $p < 0.05$) (Figure 1G). Collectively these data demonstrate a heterogeneous memory immune response
173 observed during natural infection with SARS-CoV-2.

174

175 **Antibody High versus Antibody Low subject groups**

176

177 In order to confirm the association of RBD-specific CD4 T cell responses with higher antibody levels,
178 cryopreserved PBMC and serum samples were studied from an additional 24 ADAPT subjects,
179 separated into two representative groups of 12 subjects each, with known high and low SARS-CoV-2
180 neutralisation titres, respectively, at month 3 (Supplementary Table 1). The selected antibody high (Ab
181 high) subject group had neutralisation titres NT₅₀ \geq 80, whereas the antibody low (Ab low) group had
182 neutralization titres NT₅₀ \leq 40 (Figure 2A). Neutralisation titres in the Ab high group gradually
183 decreased over time with a median of 320 at 3-month, 240 at 4-month and 120 at 8-month timepoints
184 (Figure 2B). Furthermore, the breadth of neutralizing antibodies to variants of concern was
185 significantly greater in Ab high group at 3-months (Figure 2C), but also then decreased at 8-months
186 (Figure 2D).

187

188 **Reduced RBD-specific CD4 T cell responses in individuals with low antibody levels**

189

190 We also widened our analysis of T cell responses to other SARS-CoV-2 antigens, using peptide pools
191 (Supplementary Table 2), that allowed us to adapt our CD25/OX40 CD4 assay to include the detection
192 of antigen-specific CD8 T cells by adding the co-expression of CD69 and CD137 (4-1BB) surface
193 markers (29).

194

195 RBD-specific CD4 T cells were mostly undetectable in the Ab low group (median 0.12% (3-month)
196 and 0.1% (8-month)), such that the fold difference in RBD-specific CD4 T cell responses between the 2
197 subject groups was 50-fold at month 3 ($p < 0.001$), down to 15-fold at month 8 ($p < 0.01$; Figure 3A).
198 There were also significantly higher CD4 T cell responses to the spike peptide pool in the Ab high
199 subject group compared to the Ab low subject group (Figure 3A), although not as marked as for RBD
200 (above), with a 5.3-fold higher spike-specific response at the 3-month time-point ($p < 0.01$), which was
201 still 3.9-fold higher at 8 months ($p < 0.01$; Figure 3A).

RBD-specific memory CD4 T cells

202

203 Nucleocapsid protein (NP)-specific CD4 T cell responses were not significantly different between the 2
204 groups at 3-months, but there was a 15-fold higher frequency in the Ab high subject group compared to
205 the Ab low subject group at 8-months ($p<0.01$). No difference between the 2 groups was observed in
206 the proportion of antigen-specific CD4 T cells that had a CD39⁺ Treg phenotype (30) (Supplementary
207 Figure 2).

208

209 In addition, we also measured proliferation of CD4 T cells following peptide stimulation and found that
210 there was significantly higher proliferating SARS-CoV-2-reactive CD4 T cells in the Ab high group at
211 both 3- and 8-month timepoints for all 3 peptide pools (Figure 3B). Intracellular phenotyping and
212 dimensional reduction utilising UMAP algorithm of spike-specific proliferated CD4 T cells from the
213 Ab high group showed 3 relatively large clusters of Granzyme B⁺ cells (clusters #3, #7 and #9; Figure
214 3C&D, top row) and relatively few regulatory-like cells expressing Foxp3 (clusters #2 and #4; Figure
215 3C&D, top row). In contrast, proliferated CD4 T cells, in response to the spike peptide pool, from
216 subjects in the Ab low group revealed the greatly increased presence of the 2 clusters of regulatory-like
217 cells expressing Foxp3 (clusters #2 and #4, Figure 3C&D, top row), and greatly reduced Granzyme B⁺
218 cells (clusters #3, #7 and #9, Figure 3C&D, top row), compared to the proliferated CD4 T cells from
219 subjects in the Ab high group.

220

221 Similarly, in RBD-specific proliferated CD4 T cells, the Ab high group had an increased presence of a
222 Granzyme B⁺Foxp3⁻ cluster (#6; Figure 3C&D middle rows) and less cells in Foxp3⁺ clusters (#5 and
223 #7; Figure 3C&D middle rows). The opposite was seen in the much smaller proportions of proliferated
224 cells from the Ab low group (Figure 3C&D middle rows). Nucleoprotein-specific proliferated CD4 T
225 cells also showed a very similar trend, with distinct Foxp3⁺ versus Granzyme B⁺ clusters between the
226 Ab high and low groups (Figure 3C&D bottom rows).

227

228 In CD8 T cell specific responses, defined by upregulation of CD137 and CD69, no significant
229 difference was observed between the antibody high or low groups, when stimulated with the 3 SARS-
230 CoV-2 peptide pools or influenza (Figure 4A). However, in proliferation responses, the antibody high
231 group had 4.2-fold higher proliferating NP peptide pool-specific CD8 T cells at 3 months ($p<0.01$) and
232 6.6-fold at 8 months ($p<0.05$), and a trend to higher spike-specific proliferation, compared to the
233 antibody low group (Figure 4B). The much smaller proportions of proliferated CD8 T cells from Ab

RBD-specific memory CD4 T cells

234 low subjects had clusters with much higher levels of expression of the inhibitory ligand CTLA-4,
235 compared to proliferated CD8 T cells from Ab high subjects for all 3 peptide pools (Figure 4C&D).

236

237 **B cell plasmablasts, with more CXCR5+ CD4 T cells, and T cell activation are associated with**
238 **high antibody levels**

239

240 We used 20-parameter flow cytometry to determine ex vivo phenotypic differences in the B and T cell
241 subsets of Ab high and Ab low groups. Higher frequencies of B cell plasmablasts (CD19+IgD-
242 CD27+CD38+) were found in the Ab high group (3.2-fold, $p<0.05$) at 3 months, but no difference was
243 observed at 8 months (Figure 5A). When CD19+ B cells were divided into memory subsets, there was
244 no difference at either time point for naïve (IgD+CD27-), non-switched memory (IgD+CD27+) or
245 switched memory (IgD-CD27+)(Figure 5B). However, there was higher proportion of double negative
246 (IgD-CD27-) cells in Ab low group at both 3- (1.7-fold, $p<0.05$) and 8-months (1.6-fold, $p<0.05$).

247

248 When surface markers of CD4 T cells were analysed there was significantly increased expression of
249 CXCR5 in the Ab high group at both 3- and 8-month timepoints (2.9-fold, $p<0.05$ and 2.5-fold,
250 $p<0.01$, respectively) and co-expressed activation markers HLA-DR+CD38+ (3-fold, $p<0.01$ and 1.9-
251 fold, $p<0.01$, respectively), compared to the Ab low group (Figure 5C&D). Activated CD8 T cells were
252 also increased at 3-months in Ab high subjects (2.3-fold, $p<0.05$) but not at 8-months (Figure 5E).

253

254 Within canonical CD4 T cell subsets, a higher frequency of effector memory cells (Tem; CD45RA-
255 CCR7-) was evident in the Ab high group (1.7-fold, $p<0.05$ (3-months) and 1.6-fold, $p<0.05$ (8-
256 months), compared to the Ab low group, but no difference was seen in naïve (CD45RA+CCR7+),
257 central memory (Tcm; CD45RA-CCR7+) or memory revertant cells (Temra; CD45RA+CCR7- ;
258 Figure 5F). However, naïve (CD45RA+CCR7+) CD8 T cells were significantly higher in the Ab low
259 group (1.8-fold, $p<0.05$), compared to the Ab high group, at both timepoints (Figure 5G).

260

261 To ascertain the association between the results of the T cell function assays and antibody levels,
262 Spearman's correlation was performed utilising Benjamini-Hochberg method to correct for multiple
263 comparisons. Positive correlations of antibody levels and neutralization titres were observed with: B
264 cell plasmablasts; CXCR5+ CD4 T cells; CD4 and CD8 T cell activation; and spike- and RBD-specific
265 CD4 T cell recall and proliferative responses. In contrast, DN B cells, naïve CD4 and spike-specific

RBD-specific memory CD4 T cells

266 CD8 recall responses were all negatively correlated with antibodies (Figure 5H). These same
267 parameters were able to separate Ab high and low groups using PCA (Figure 5I).

268

269 **Single-cell RNAseq revealed heterogeneity and TCR diversity in SARS-CoV-2 reactive CD4 T** 270 **cells**

271

272 Our previous observations showed that CD4 T cell recall responses to SARS-CoV-2 positively
273 correlated with greater humoral responses, in particular RBD-specific responses in the Ab high subject
274 group. To better understand these antigen-specific CD4 T cells, especially those specific for RBD, we
275 sorted CD25+CD134+ CD4 T cells from 4 representative subjects from the Ab high group, following
276 stimulation with peptide pools at 44hrs. Unstimulated purified memory CD4 T cells were used as the
277 comparison population (Supplementary Figure 3A&B). Single-cell RNAseq was performed on a total
278 of 14,053 cells comprising: (i) 9,039 ex vivo (unstimulated) memory cells; (ii) 2,026 NP-specific cells;
279 (iii) 1,989 spike-specific cells; and (iv) 999 RBD-specific cells. Analysis of 10x transcriptomics was
280 coupled with TCR α/β sequencing. We found heterogeneous subsets of CD4 T cells that were reactive
281 to spike, RBD and NP; comprising transitional memory, central memory, Treg and cytotoxic subsets
282 (Figure 6 A&B). Enrichment of activated GITR+ Tregs (cluster 3) was particularly evident in the
283 stimulated conditions (48.15%, 62.34% and 54.94% for NP- Spike- RBD-specific cells, respectively),
284 compared to 3.08% for ex vivo memory cells (Figure 6C).

285

286 Analysis of TCR annotation was achieved on 11,824 single cells (84.14%). Diverse TCR responses
287 resulted from all 3 stimulation conditions with similar Shannon Entropy score for the stimulation
288 conditions compared to the unstimulated ex vivo (Supplementary Figure 4A) and diverse TCR α/β
289 pairings for all four conditions (Supplementary Figure 4B). To examine if TCR α/β V gene was altered
290 in the stimulated conditions compared to ex vivo memory, log odds-ratio analysis was performed with
291 Bonferroni's correction. No difference was observed in the majority of TCR α/β V genes between ex
292 vivo memory and stimulated conditions. However, there was increased usage of TCR α TRAV1-
293 2/34/39 chains evident in NP-specific CD4 T cells compared to ex vivo memory (Figure 6D), while
294 TRBV10-2 was the only TCR β chain enriched in RBD-specific CD4 T cells (Figure 6E). With the
295 exception of CD4 CTLs, where approximately half of the ex vivo unstimulated clones were re-sampled
296 post-stimulation, generally antigen-specific clonotypes within the ex vivo unstimulated memory cell
297 pool comprised only a tiny fraction of the antigen-specific clonotypes sampled following 2 days of

RBD-specific memory CD4 T cells

298 antigen stimulation (Figure 6F). Clonotypes shared between unstimulated ex vivo CD4 memory and
299 antigen specific pools rarely displayed altered cellular phenotypes following stimulation (Figure 6F).

300

301

302 **Proliferative CD4 T cell clonotypes are enriched within cytotoxic and Treg subsets**

303

304 To examine the clonal diversity of proliferative CD4 T cell subsets and confirm the single cell RNAseq
305 clonotype data, we performed bulk TCR sequencing on T cells proliferating in response to NP, spike
306 and RBD, compared to an unstimulated control, from the same 4 patients as for the 10X
307 transcriptomics. The TCR clonotypes found to be enriched by proliferation in the stimulated
308 conditions compared to unstimulated were then matched to the same clonotype previously identified
309 via 10X transcriptomics and overlaid on the same UMAP (Figure 7A).

310

311 10% of clonotypes were shared between the single cell RNAseq analysis and the proliferation assay
312 TCR analysis. Enriched proliferative clonotypes identified in the SARS-CoV-2 antigen-stimulated
313 cultures were most frequent in transcriptomic clusters comprising: (i) conventional Granzyme B+ CD4
314 CTL (cluster 2; Figure 7B), (ii) CD4/CD8 double positive CTL (cluster 0; Figure 7B); and (iii)
315 relatively limited proliferation of activated GITR+ Tregs, compared to their identification in the OX40
316 assay 10x only analysis (cluster 3; Figure 7B). The majority of clonotypes identified through the single
317 cell RNAseq analysis were unique singletons, while expanded clonotypes following proliferation
318 consisted mostly of 2 cells with the same clonotype, as well as a small portion of clonotypes that were
319 2-5 cells (Figure 7C).

320

321 As expected, there was very little overlap of TCR clonotypes between the different antigen-specific
322 responses, with <1% of clonotypes being shared (Figure 7D), consistent with high diversity within
323 SARS-COV-2 reactive CD4 T cells. A total of 3, 599 unique SARS-CoV-2 clonotypes were identified
324 in our study that have not been previously reported elsewhere.

325

326 **Increased RBD-specific CD4 T cells following vaccination**

327

328 It was then important to assess whether vaccination would improve adaptive immune responses in the
329 low antibody ADAPT convalescent subjects. Between 2 and 4 weeks following the vaccination second
330 dose of either BNT162b2 or ChAdOx1, PBMC samples were collected from the previously infected

RBD-specific memory CD4 T cells

331 participants, from either the high or low antibody patient groups, respectively. No longitudinal
332 difference was observed between either spike or NP-specific CD4 T cell responses at D2 timepoint (2-4
333 weeks post-second dose) in both subject groups. However, in RBD-specific responses, in the original
334 Ab low group, there was a 3.4-fold increase from the 8-month convalescent timepoint to the post-
335 vaccination D2 timepoint ($p<0.01$; Figure 8A). No difference was observed in CD8 T cell response
336 between pre or post vaccination timepoints (Figure 8B).

337

338 A sharp increase in neutralizing antibody titres towards the ancestral strain was observed in both Ab
339 high and low groups after vaccination (Ab high 8M $NT_{50}=160$, D2 $NT_{50}=640$ [$p<0.01$]; Ab low 8M
340 $NT_{50}=40$, D2 $NT_{50}=960$ [$p<0.0001$]). Neutralization of the B.1.617.2 delta strain was also increased
341 (Ab high 8M $NT_{50}=80$, D2 $NT_{50}=320$ [$p<0.01$]; Ab low 8M $NT_{50}=0$, D2 $NT_{50}=480$ [$p<0.0001$]) (Figure
342 8C). As it was previously shown that low RBD-specific CD4 T cells response was associated with low
343 neutralizing antibodies at 3- and 8-months post-infection, it was important to correlate these two
344 parameters at the post-vaccination timepoint. A positive correlation (spearman's $\rho=0.36$, $p<0.05$) was
345 observed between RBD-specific CD4 T cells in the OX40 assay and neutralization titre post-second
346 dose (D2) timepoint (Figure 8D).

347

348

RBD-specific memory CD4 T cells

349 **DISCUSSION**

350

351 This study has revealed that only those convalescent COVID-19 patients who had readily detectable
352 RBD-specific CD4 T cell in vitro recall responses had significantly higher neutralizing antibody titres,
353 whereas lower anti-spike antibody levels, especially neutralizing antibody titres, were associated with a
354 lack of RBD-specific proliferative CD4 T cells . These results raise serious questions of the quality and
355 quantity of any immediate anamnestic in vivo response in patients without these proliferative CD4 T
356 cell responses, if re-exposed to SARS-CoV-2. In contrast, those patients with in vitro proliferative
357 RBD-specific CD4 T cells would be predicted to mount an early vigorous in vivo immune response if
358 re-exposed. Other groups using similar assays to our OX40 assay (*12-16*) have also found that the
359 majority of recovered COVID-19 patients had detectable responses to pools of spike peptides, but with
360 only a subset of patients having CD4 T cell responses to RBD epitopes. We have also previously
361 shown that early CD4⁺ T cell responses can predict RBD-specific memory B cell frequencies at 1-year
362 post-infection (*31*).

363

364 It is widely believed that neutralizing antibodies are the first line of defence against re-infection with
365 the same viral pathogen (*4*). Our results agree with other studies that there is a very large variation in
366 levels of such neutralizing antibodies in the serum of individuals recovered from COVID-19 (*28*); the
367 reasons for this range of responses are unknown, but the quantity and quality of viral antigen-specific
368 CD4 T cells are highly likely to be important (*5*). Furthermore, it is unknown what level of such
369 antibodies are required for complete protection. However, with the current vaccines, and evidence from
370 their Phase III trials, a correlation of higher neutralization titres and lower infection rates has been
371 reported (*32*).

372

373 Our results directly correlate RBD-specific proliferative CD4 T cell responses in convalescent PBMC
374 with anti-spike antibodies and neutralizing antibody titres. Furthermore, spike-specific CD4 T cells
375 from recovered COVID-19 subjects with low antibody levels showed very little expansion in vitro, and
376 in the smaller number of cells that did proliferate, they appeared to relatively highly express the Treg
377 transcription factor Foxp3. Our CD25/OX40 assay was able to identify SARS-CoV-2-specific Tregs,
378 using CD39 expression (*30*), which was confirmed at the transcriptional level with Foxp3 and GITR
379 expression. Treg responses have been under-represented in other studies using other activation markers,
380 namely CD40L (CD154) and 4-1BB (CD137) (*23, 33-35*), together with shorter incubations with
381 antigens, that did not pick up these important regulatory cells. Further studies are needed to understand

RBD-specific memory CD4 T cells

382 whether a preponderance of Tregs exerts a greater influence over a smaller number of spike-specific
383 proliferation-capable CD4 T cells from the Ab low subjects.

384

385 When SARS-CoV-2 spike-, RBD- and NP-specific CD4 T cells from patients from the high Ab group
386 were examined at the single cell transcriptomic level, heterogeneous profiles of CD4 T cell subsets
387 were observed that included central memory cells and CD4 CTL, as well as regulatory T cell
388 populations expressing GITR and Foxp3. Importantly, the specific CD4 and CD8 T cells from patients
389 from the antibody low group showed a predominance of expression of Foxp3 and CTLA-4,
390 respectively, associated with their limited proliferative responses. We have previously reported high
391 CTLA-4 expression in HIV-specific CD4 T cells (36) which was inhibitory to proliferative responses in
392 vitro (37), whereas vaccinia-specific CD4 T cells expressed less CTLA-4 and proliferated well, 21 days
393 after inoculation (7).

394

395 T follicular helper cells (Tfh) are vital in B cell maturation and immunoglobulin class switching
396 within the germinal centre (5), Two studies have suggested that circulating Tfh (cTfh) from recovered
397 COVID-19 patients include spike-specific CD4 T, but in one study RBD-specific cTfh were rare (12)
398 while in the other, total spike-specific cTfh were only seen in 3/26 subjects (38), overall consistent with
399 a large proportion of immunodominant epitopes for the spike-specific CD4 T cells being outside the
400 RBD (12, 39). Interestingly, one study has reported an immunodominant CD4 epitope within RBD
401 from convalescent PBMC, using in vitro proliferation in response to spike peptides, as an initial step in
402 a cloning procedure (20), but antibody levels were not reported.

403

404 We were able to characterize in detail the expanded RBD-specific CD4 T cells after in vitro
405 proliferation and, surprisingly, we found no staining for the Tfh-defining transcription factor Bcl6 in
406 the expanded cells from PBMC, despite using staining protocols that readily identified Bcl6+ Tfh and
407 germinal centre B cells in other studies of lymph node (40, 41) and tonsil cells (42). In a previous
408 study, we also identified *BCL6* at the single cell level in antigen-specific CD4 T cells in PBMC (43).
409 Therefore, we postulated that spike-specific cTfh cells should be encompassed within the CXCR5+ and
410 activated central memory subsets, observed from our single cell RNAseq data, but low transcript
411 expression of *BCL6* did not give us a definitive answer. Nevertheless, future in vitro studies should
412 examine whether memory CD4 T cells in PBMC, in particular cTfh, from recovered COVID-19
413 patients, can boost anti-spike antibodies by memory B cells in vitro, analogous to previous studies for
414 other recall antigens (44). Instead, our analysis of proliferated RBD-specific CD4 T cells showed they

RBD-specific memory CD4 T cells

415 were more likely to highly express T-bet, the Th1-defining transcription factor. Most studies have
416 reported that IFN- γ is the most prominent cytokine produced by SARS-CoV-2 specific memory T cells
417 in vitro in response to antigen (12-15), so expression of T-bet in expanded cells is consistent with a Th1
418 skewing of spike-specific effector CD4 T cells in PBMC.

419

420 We have previously shown that there are relatively high expression of cytotoxic lymphocyte markers in
421 HIV-specific and CMV-specific CD4 T cells (45-47), as well as CD4 CTL found in other viral
422 infections (reviewed recently in (48)). Very early following vaccinia inoculation, many vaccinia-
423 specific CD4 T cells were also CTL, expressing mainly Granzyme K, at day 14, at the same time as the
424 peak of activated CD4 T cells in blood (8), consistent with what was reported for a COVID-19 patient
425 during the acute phase of the infection (49). We identified three transcriptomic clusters of cytotoxic
426 CD4 T cells that were within the SARS-COV-2 reactive subsets by single cell RNAseq. This
427 observation was consistent with our finding of in vitro expanded spike-specific CD4 T cells that
428 expressed protein markers of cytotoxic T lymphocytes (CTL), including the granzymes A and B, and
429 perforin, and cytotoxic granules (as defined by the antibody TIA-1, which recognizes the protein
430 encoded by the gene *NKG7* (45, 50)). Highly enriched proliferative clonotypes were also shown to
431 overlap with conventional CD4 CTL and CD4/8 double positive CD4 CTL by single cell RNAseq. It
432 was also evident following bulk TCR-seq that proliferated clonotypes in response to spike and RBD
433 were enriched within CD4 CTL clusters. Effector CD4 T cells expressing cytotoxic granules have been
434 identified in other single cell transcriptomic studies (35, 51), suggesting that CD4 CTLs may play an
435 important role in eliminating SARS-CoV-2 infected cells.

436

437 Based on what is known about CD4 T cell help for B cell responses (5), it is highly likely that memory
438 CD4 T cells in peripheral blood reflect a large CD4 T cell response in draining lymph nodes, including
439 T follicular helper cells (Tfh), but also resulting in exit of antigen-specific effector and memory cells
440 into the circulation. We have directly observed these highly activated, non-Tfh cells in lymph nodes in
441 untreated HIV-1 infection (40, 42), but their clonal relationship to similarly elevated Tfh cells is still
442 under study. From the current study, it isn't clear at the molecular level why CD4 T cells with
443 specificities to epitopes within RBD may generate better levels of anti-spike neutralizing antibodies.
444 Theoretically, any spike-specific CD4 T cells should be able to help B cells that are able to take up
445 spike protein via specificity for RBD. However, spike protein is very large and is designed to be
446 cleaved during viral entry into target cells, involving multiple proteases (52-54), so it is possible that
447 spike available for B cell recognition in germinal centres may also be cleaved to smaller protein

RBD-specific memory CD4 T cells

448 fragments, only some of which link B cell and T cell epitopes around RBD. Clearly this needs further
449 study with defined epitopes, along with the clonal relationships between germinal centre Tfh cells
450 during acute infection and memory cells during convalescence. While early studies suggested that there
451 can be intermolecular CD4 help for antibody responses in murine models of influenza infection (55,
452 56), in a vaccinia virus mouse model it was shown clearly that intramolecular CD4 help was required
453 for antibodies to individual viral proteins from this large poxvirus (57). Most studies of SARS-CoV-2
454 specific T cells have used large peptide pools, whereas we have found most of our associations with
455 recombinant proteins which may be an advantage because it requires the full antigen-processing and
456 HLA Class II presentation pathway rather than extracellular saturation with a large number of
457 exogenous peptides. Finally, it also has to be considered whether some RBD epitopes may be obscured
458 by glycan residues that lock the RBD in a “down” position (58), since our recombinant proteins were
459 made in human cell lines.

460

461 Possible reasons why some infected individuals have low adaptive immune responses could be due to
462 (i) lower initial viral loads during first wave infections compared to later waves of variants (59); (ii)
463 antigen presentation to CD4 T cells is dominated by epitopes in spike fragments outside of RBD (39,
464 60); and (iii) possibly having more inhibitory and/or exhausted B and T cells (23).

465

466 Importantly, however, it appears that RBD-specific CD4 T cells could be boosted by vaccination. Our
467 results suggest that booster efficacy would be improved by concentrating on CD4 T cell epitopes in and
468 around the RBD, which may be the optimal regimen for generation of neutralizing antibodies.

469

RBD-specific memory CD4 T cells

470 **MATERIALS AND METHODS**

471

472 **ADAPT Cohort**

473

474 The ADAPT study is a prospective cohort study of post-COVID-19 recovery established in April 2020
475 (61), with ongoing recruitment (147 participants with confirmed SARS-CoV-2 infection had been
476 enrolled at the time of writing). The majority were recruited following testing in community-based
477 clinics run by St Vincent's Hospital Sydney, with some patients also enrolled with confirmed infection
478 at external sites. Initial study follow-up was planned for 12 months post-COVID-19, and subsequently
479 extended to 2 years. Extensive clinical data was systematically collected, including classification of
480 disease severity, as previously described (61) and a prospective biorepository established, as previously
481 described (62). Subjects classified with mild COVID-19 were those managed in the community with
482 minor, largely upper respiratory tract viral symptoms, including pharyngitis, rhinorrhea, headache, and
483 anosmia/ageusia. Subjects with moderate COVID-19 were managed in the community with fever/chills
484 and one of the following organ-localizing symptoms, or at least two of the following organ-localizing
485 symptoms: cough, hemoptysis, shortness of breath, chest pain, nausea/vomiting, diarrhea, altered
486 consciousness/confusion. Subjects with severe COVID-19 were those who required inpatient care
487 (wards or intensive care unit), as previously described (61). Laboratory testing for SARS-CoV-2 was
488 performed using nucleic acid detection from respiratory specimens with the EasyScreen™ SARS-CoV-
489 2 Detection kit (Genetic Signatures, Sydney, Australia). Enrolment visits were performed at median 76
490 (IQR 64-93) days after initial infection (3-months) and 8-month assessments were performed at median
491 232 (IQR 226-253) days after initial infection. Serum and PBMCs were collected from ADAPT study
492 participants following vaccination with either 2 doses of BNT162b2 (Pfizer) or ChAdOx1
493 (AstraZeneca).

494 The demographics of the ADAPT study participants in this report (first wave patients, recruited prior to
495 October, 2020) are shown in Supplementary Table 1. Unexposed healthy adult donors (n=13; 45%
496 male; median age 46) were recruited through St Vincent's Hospital, were anti-spike antibody negative,
497 and tested prior to vaccination.

498

499 **Ethics**

500

501 The ADAPT study was approved by the St Vincent's Hospital Human Research Ethics Committee
502 (2020/ETH00964) and is a registered trial (ACTRN12620000554965). ADAPT-C sub study was

RBD-specific memory CD4 T cells

503 approved by the same committee (2020/ETH01429). All data were stored using REDCap electronic
504 data capture tools. Unexposed healthy adult donors were recruited through St Vincent's Hospital which
505 was approved by St Vincent's Hospital Human Research Ethics Committee (HREC/13/SVH/145 and
506 HREC/10/SVH/130). All participants gave written informed consent.

507

508 **Antigens**

509

510 Recombinant SARS-CoV-2 RBD polypeptide was produced using DNA encoding a His-tagged 200
511 amino acid region, for residues 319 to 541 of SARS-CoV-2 S protein, as previously described (63),
512 corresponding to the following amino acid sequence: RV QPTESIVRFP NITNLCPFGE
513 VFNATRFASV YAWNRRKRISN CVADYSVLYN SASFSTFKCY GVSPTKLNLDL CFTNVYADSF
514 VIRGDEVQRQI APGQTGKIAD YNYKLPDDFT GCVIAWNSNN LDSKVGGNYN YLYRLFRKSN
515 LKPFERDIST EIYQAGSTPC NGVEGFNCYF PLQSYGFQPT NGVGYQPYRV VVLSFELLHA
516 PATVCGPKKS TNLVKNKCVN FG SHHHHHH, which was cloned into pCEP4 vector (Thermo
517 Fisher) and expressed transiently in Expi293 cells (Thermo Fisher) using the Expifectamine
518 transfection kit (Thermo Fisher). After 7 days of expression, the culture supernatant was filtered,
519 dialysed against PBS and the protein purified using the His-tag and Talon resin (Thermo Fisher), as
520 previously described (63).

521 Recombinant trimeric SARS-CoV-2 spike protein was expressed from a plasmid encoding the spike
522 protein with C-terminal trimerization domain and His tag which was a gift from the Krammer lab (BEI
523 Resources, NIAID, NIH). The plasmid was transfected into Expi293 cells and protein expressed for 3
524 days at 37°C, 5% CO₂. The protein was purified using the His tag as for the RBD purification. The
525 protein was further purified on a Superose 6 gel filtration column (GE Healthcare) using an AKTA
526 Pure FPLC instrument (GE Healthcare) to isolate the trimeric protein and remove S2 pre-fusion
527 protein, as previously described (63). Pools of 15-mer peptides corresponding to the sequence of
528 SARS-CoV-2 spike protein were purchased from Genscript (Hong Kong) and are listed in
529 Supplementary Table 2. His-tagged purified recombinant spike proteins from human coronavirus
530 strains 229E, NL63 and OC43 were purchased from SinoBiologicals US (Wayne, PA, USA). Anti-
531 CD3/anti-CD28/anti-CD2 polyclonal T cell activator was purchased from StemCell Technologies
532 (Vancouver, Canada). Purified Influenza A (A/Sydney/5/97) was a gift from Alan Hampson, CSL, as
533 previously described (19).

534

535 **CD25/OX40 assay**

RBD-specific memory CD4 T cells

536

537 Peripheral blood mononuclear cells (PBMC) were isolated from EDTA anti-coagulated blood within 4
538 hr of venepuncture, as previously described (8). Antigen-specific CD4 T cells responding to recall
539 antigens, simultaneously up-regulating CD25 and CD134 (OX40), were measured in cultures of
540 300,000 PBMC in 200 μ l/well of a 96-well plate, in Iscove's Modified Dulbecco's Medium (IMDM;
541 Thermofisher, Waltham, MA, USA) containing 10% human serum (kind gift, Dr Wayne Dyer,
542 Australian Red Cross Lifeblood, Sydney, Australia), which were incubated for 44-48 hr, in a 5% CO₂
543 humidified incubator, as previously described (19). Separate cultures were incubated with individual
544 SARS-CoV-2 antigens as indicated. All experiments additionally included: (i) a culture medium only,
545 negative control well; (ii) anti-CD3/anti-CD28/anti-CD2 T cell activator (1/200 dilution), polyclonal
546 positive control well; and (iii) influenza virus (1/200 dilution), antigen positive control well. PBMC
547 from the respective cultures were stained with CD3-PerCP-Cy5.5, CD4-FITC, CD25-APC, and
548 CD134-PE (BD Biosciences, San Jose, CA, USA) and run on a 5-laser Fortessa X20 (BD Biosciences)
549 as previously described (64). Antigen-specific CD4 T cells were gated and expressed as
550 CD25+CD134+ % of CD4+ CD3+ T cells as previously described (19). Cultures were classified as
551 positive for antigen-specific CD4 T cells if the CD25+CD134+ % of CD4+ CD3+ T cells was \geq 0.2%
552 (65).

553

554 **Cell Trace Violet (CTV) proliferation assays**

555

556 PBMC were resuspended at a concentration of 10×10^6 /ml in PBS and incubated with Cell Trace
557 Violet (CTV) dye (Thermofisher) at 5 μ M for 20 min at RT, according to the manufacturer's
558 directions. Cells were washed once with 5x volume of IMDM/10% human serum and resuspended for
559 cultures of 300,000 PBMC in 200 μ l/well of a 96-well plate and incubated for 7 days in a 5% CO₂
560 incubator. Different wells contained different antigens as indicated. All experiments also included: (i)
561 culture medium only negative control well; (ii) anti-CD3/anti-CD28/anti-CD2 T cell activator (1/200
562 dilution) polyclonal positive control well; and (iii) influenza virus (1/200 dilution) antigen positive
563 control well. After 7 days, cells from the respective cultures were stained with CD3-PerCP-Cy5.5,
564 CD4-FITC, CD8-APC-H7 and CD25-APC (BD Biosciences), and analysed on a 5-laser Fortessa X20
565 (64) and antigen-specific CD4 T cells gated as CD3+CD4+CD25^{high}CTV^{dim} as previously described
566 (66). Cultures were classified as positive for antigen-specific CD4 T cells if the CD25^{high}CTV^{dim} % of
567 CD4+ CD3+ T cells was \geq 1%.

568

RBD-specific memory CD4 T cells

569 **Intracellular analysis of transcription factors**

570

571 Expanded CD25^{high}CTV^{dim} antigen-specific CD4⁺ CD3⁺ T cells at the end of a 5 day incubation period
572 were analysed for expression of intracellular markers including transcription factors, cytotoxic effector
573 molecules and CTLA-4 using Transcription Buffer permeabilization reagents (BD Biosciences),
574 according to the manufacturer's directions. The monoclonal antibodies used were: Tbet-BV711
575 (BioLegend); RORgT-PE and CTLA-4-PECy5 (BD Biosciences); Eomes-PE-Cy7, Bcl6-PerCP-eFluor
576 701 and Foxp3-AF700 (eBiosciences, ThermoFisher). Following intracellular staining, cells were
577 resuspended in 1% paraformaldehyde/PBS and analysed on the 5-laser Fortessa X20.

578

579 **Ex vivo phenotyping and combined CD4/CD8 T cell activation assay**

580

581 Cryopreserved PBMCs were thawed using RPMI medium containing L-glutamine and 10% FCS
582 (ThermoFisher Scientific, USA) supplemented with Penicillin/Streptomycin (Sigma-Aldrich, USW),
583 and subsequently stained with antibodies binding to extracellular markers. Extracellular panel included:
584 Live/Dead dye Near InfraRed, CXCR5 (MU5UBEE), CD38 (HIT2) (ThermoFisher Scientific, USA);
585 CD3 (UCHT1), CD8 (HIL-72021), PD-1 (EH12.1), TIM-3 (TD3), CD27 (L128), CD45RA (HI100),
586 IgD (IA6-2), CD25 (2A3), and CD19 (HIB19) (BioLegend, USA); CD4 (OKT4), CD127 (A019D5),
587 HLA-DR (L234), GRP56 (191B8), CCR7 (G043H7) and CD57 (QA17A04) (BD Biosciences, USA).
588 FACS Perm Buffer II (BD Pharmingen) was used for intracellular staining of granzyme B (GB11, BD
589 Biosciences). FACS staining of 48hr activated PBMCs was performed as described previously, but
590 with the addition of CD137 (4B4-1) to the cultures at 24hrs. Final concentration of 10µg/mL of SARS-
591 CoV-2 peptide pools (Genscript) were used, 1 µg/mL of Influvac tetra influenza vaccine (Mylan
592 Health, Sydney, Australia) was used as a control antigen and staphylococcal enterotoxin B (SEB; 1
593 µg/ml) was used as a positive control (Thermo Fisher Scientific). In vitro activation mAb panel
594 included: CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD39 (A1), CD69 (FN50) all BioLegend,
595 CD25 (2A3), CD134 (L106)- BD Biosciences. Samples were acquired on the Aurora CS spectral flow
596 cytometer (Cytek Biosciences, USA) using the Spectroflo software. Prior to each run, all samples were
597 fixed in 0.5% paraformaldehyde. Data analysis was performed using FlowJo version 10.7.1 (TreeStar).

598

599 **Anti-Spike diagnostic serology**

600

RBD-specific memory CD4 T cells

601 Antibodies to SARS-CoV-2 spike in serum samples from ADAPT subjects were measured using the
602 LIAISON® SARS-CoV-2 S1/S2 IgG diagnostic assay (Diasorin, Saluggia, Italy), according to the
603 manufacturer's direction. This method quantitatively detects IgG anti-S1 and anti-S2 specific
604 antibodies by indirect chemiluminescence immunoassay, using recombinant S1 and S2 antigens.

605

606 **Flow cytometry based IgG/IgM serology**

607

608 The assay to detect patient serum antibodies against SARS-CoV-2 antigens using flow cytometry has
609 been previously described in detail (28). Briefly, HEK293 cells were transfected to transiently express
610 SARS-CoV-2 full-length Spike (Wuhan-1 D614), Membrane and Envelope proteins. Diluted patient
611 serum was added to the cells, followed by adding AlexaFluor 647-conjugated anti-human IgG (H+L)
612 (Thermo Fisher Scientific) or anti-human IgM (A21249, Thermo Fisher Scientific). The LSRII flow
613 cytometer (BD Biosciences, USA) was used to acquire the cells and patients were confirmed SARS-
614 CoV-2 antibody positive if, in at least two of three quality-controlled experiments, their median
615 fluorescence intensity ($\Delta\text{MFI} = \text{MFI transduced cells} - \text{MFI untransduced cells}$) was above the
616 positive threshold (mean $\Delta\text{MFI} + 4\text{SD}$ of 24 pre-pandemic controls). Data were analysed using FlowJo
617 10.4.1 (TreeStar, USA), Excel (Microsoft, USA), and GraphPad Prism (GraphPad Software, USA).

618

619 **Live virus neutralization assay**

620

621 HEK293T cells were transduced with lentiviral particles to stably express human ACE2 and
622 TMPRSS2. Briefly, the lentiviral expression vectors pRRLsinPPT.CMV.GFP.WPRE (Follenzi et al.,
623 2002) and pLVX-IRES-ZsGreen (Clontech) were used to clone the ORFs for hACE2 (Addgene#1786)
624 and hTMPRSS2a (Addgene#53887, synthetic gene fragment;IDT), respectively. Lentiviral particles for
625 transduction, to express the above proteins, were produced by co-transfecting the second generation
626 lentiviral packaging constructs psPAX2 (courtesy of Dr Didier Trono through NIH AIDS repository)
627 and VSVG plasmid pMD2.G (Addgene#2259) and the expression plasmids individually in HEK293T
628 cells (Life Technologies) using polyethyleneimine, as previously described (67). To generate the
629 HEK293/ACE2/TMPRSS2a cells, two successive rounds of lentiviral transductions were performed;
630 the highly permissive clone, HekAT24 was identified by clonal selection and then used to carry out the
631 SARS-CoV-2 neutralisation assay as previously described (67).

632

RBD-specific memory CD4 T cells

633 To perform the assay, HekAT24 cells were trypsinized and while in suspension stained with Hoechst-
634 33342 dye (5% v/v) (NucBlue, Invitrogen) and then seeded in a 384-well plate (Corning #CLS3985) at
635 16,000 cells per well in 40 μ L of DMEM-5% FCS. Patient plasma samples were mixed at two-fold
636 dilutions with an equal volume of SARS-CoV-2 virus solution (4×10^3 TCID₅₀/ml). Following
637 incubation at 37°C for 1 hour, 40 μ L were transferred in duplicate to the cells (final MOI = 0.05). The
638 following variants of concern were included as viral variants: Beta (B.1.351), Gamma (P.1), Delta
639 (B.1.617), as well as control virus from the same clade with matching ‘D614G’ background (B1.319).
640 Following 24 hours of incubation, entire wells were imaged by high-content fluorescence microscopy
641 and an automated image analysis software obtained the cell counts. The following formula was used to
642 calculate the percentage of virus neutralisation: %N = (D-(1-Q)) \times 100/D, where Q = nuclei count
643 normalized to mock controls and D = 1-Q for average of infection controls as previously described
644 (67). Neutralisation activity, NT₅₀ was defined as the serum dilution that led to 50% neutralization of
645 infection.

646

647 **Dimensional Reduction and Clustering Analysis**

648 FCS3.0 files were compensated manually using acquisition-defined matrix as a guide, and gating
649 strategy was based on unstained or endogenous controls. Live singlets were gated from proliferated
650 CD25+CTV- CD4+, or CD8+, respectively, CD3+ T cells using FlowJo v.10.7.2, samples were
651 decoded and statistical analysis between groups and unsupervised analysis was performed. For
652 unsupervised analysis, the following FlowJo plugins were used: DownSample (v.3), UMAP (v.0.2),
653 Phenograph (v.3.0) and ClusterExplorer (v.1.5.9) (all FlowJo LLC). Equal number of events for each
654 condition were taken from each grouped sample by down sampling. The two new FCS files
655 corresponding to Ab high and Ab low were then concatenated for dimensionality reduction analysis
656 using UMAP. UMAP was conducted using the following parameters for proliferated CD4 T cells: T-
657 bet, Eomes, Granzyme B, Foxp3, ROR γ t, and BCL-6; and for CD8+ T cells: T-bet, Eomes, Granzyme
658 B and CTLA-4. The Phenograph plugin was then used to determine clusters of phenotypically related
659 cells. The same markers as TriMap and parameters k = 152 and Run ID = auto was used for analysis.
660 Finally, ClusterExplorer plugin was used to identify the phenotype of the clusters generated by
661 Phenograph.

662 **Single cell RNA-seq analysis of antigen-specific T cells**

663

RBD-specific memory CD4 T cells

664 PBMC from 4 Ab high donors were cultured for 48 hr with NP, spike and RBD peptide pools,
665 respectively (Supplementary Table 2), as for the OX40 assays (see above). A total of 14,053 SARS-
666 COV-2 specific CD25+OX40+ CD4 T cells from these cultures were purified using FACSARIAIII cell
667 sorter (BD biosciences), as shown in Supplementary Fig 2A. Unstimulated purified CD45RO+ ex vivo
668 memory CD4 T cells were used as a comparator subset (Supplementary Fig 2B). Purity of sorted
669 populations were >99%. Populations were individually stained with Total-Seq C hashtags (BioLegend),
670 and single cell libraries were generated using the 5'v2 Gene expression and immune profiling kit (10x
671 Genomics). Subsequent cDNA and TCR libraries were generated according to manufacturer's
672 instructions. Generated libraries were sequenced on the NovaSeq S4 flow cell (Illumina) at Read 1 =
673 28, i7 index = 10, i5 index = 10 and Read 2 = 90 cycles according to manufacturer's instructions.

674

675 **Transcriptomic analysis**

676

677 *Pre-processing of raw sequencing files*

678 Single-cell sequencing data was aligned and quantified using Cell Ranger (10x Genomics) against the
679 human reference genome (10x Genomics, July 7, 2020 release) with default parameters. Raw hashtag
680 data was processed using CITE-Seq count algorithm (68). Cell conditions were demultiplexed using
681 'HTODemux' function implemented in Seurat (68). Filtering and quality control was performed using
682 Seurat (69) on data containing 15,276 cells where 14,053 cells were retained satisfying thresholds of
683 both <10% mitochondria content and number of genes between 300 and 5000. 'SCTransform' was
684 used for normalization (70). Genes encoding BCR and TCR were removed to improve cell clustering.
685 Principal Component Analysis (PCA) dimensional reduction was performed on variable genes
686 identified by 'VariableFeatures' function and cell clusters were visualised using Uniform Manifold
687 Approximation and Projection (UMAP) clustering implemented in Seurat (69).

688

689 *Annotation of cell identities and Differential gene expression analysis*

690

691 T cell sub-populations were manually annotated based on UMAP clustering and markers defined by
692 'FindAllMarkers' function in Seurat.

693 Raw counts from defined cell populations were normalised using scran / scater (71, 72) and differential
694 gene expression analysis was performed using Limma voom (73).

695

696 **TCR analysis of bulk proliferated cells**

RBD-specific memory CD4 T cells

697 RNA was extracted from bulk proliferated cultures using RNAeasy micro kit (Qiagen) as per
698 manufacturer's instructions. TCR high throughput RNA sequencing methods have been previously
699 published in detail (74). Briefly, reverse transcription of RNA was performed using a modified
700 SmartSeq2 protocol that incorporated a 10bp universal molecular identifiers (UMI) into cDNA
701 molecules. The first round of PCR was performed using primers against adapter sequences
702 incorporated during cDNA synthesis with 1x KAPA HiFI HotStart ReadyMix and 8.3 mM Fwd and
703 Rev primer with the following conditions: 98°C for 3 min; [98°C for 20 s, 67°C for 15 s, 72°C for 6
704 min] x 10 cycles; 72°C for 5 min. Purified PCR products were used in a second PCR targeting the
705 TCR β chain under the following conditions: 98°C for 45 s; [98°C for 15 s, 60°C for 30 s, 72°C for 30
706 s] x 30 cycles; 72°C for 1 min. Purified PCR products were then barcoded using the Nextera Index kit
707 to enable pooling of multiple samples and sequenced on an Illumina MiSeq at 300bp paired-end reads
708 to a depth of ~0.5 million read pairs per sample. Primer sequences were as previously described (74).

709 **Analysis of single cell and bulk TCR datasets**

710
711 Bulk TCRB datasets for the proliferation assay were processed with the Presto package (version 0.7.0
712 2021.10.28) (75). Reads were filtered for a minimum quality score of 20 using FilterSeq. R2s were
713 trimmed of the TRC primer using MaskPrimers requiring exact primer matches. MaskPrimers was also
714 used to extract the 10 nucleotide UMIs from R1 and to trim to TSO sequences. Trimmed R1 and R2
715 were paired with PairSeq and consensus UMIs were defined with BuildConsensus. R1 and R2 were
716 then merged with AssemblePairs and the dataset was dereplicated to unique sequences and converted
717 from fastq to fastq with CollapseSeq. Sequences with ambiguous bases (n) were discarded.
718 Dereplicated fasta datasets were aligned against the IMGT human TCR reference directory
719 [<https://www.imgt.org/vquest/refseqh.html>, downloaded 16-Jan-2020] using IgBLAST (76) via
720 AssignGenes to generated AIRR formatted output.

721
722 To ensure consistent gene calling, TCR contigs from 10x's cellranger vdj were re-aligned to the IMGT
723 human TCR reference set with AssignGenes from the Presto package. Change-o databases were
724 generated with MakeDb and subset to TCRA and TCRB with ParseDb from the Change-o package
725 (version 1.2.0 2021.10.29) (77).

726
727 TCR clonotypes were defined using the TCRV, TCRJ and CDR3 AA sequence. Clonotype information
728 from 10x VDJ was integrated with the 10x scRNA-seq within the Seurat package (version 4.1.0) (78)

RBD-specific memory CD4 T cells

729 in R [R Core Team (2020). R: A language and environment for statistical computing. R Foundation for
730 Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>] using RStudio [RStudio
731 Team (2021). RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA URL
732 <http://www.rstudio.com/>] based on shared cell barcodes. For the proliferation assay bulk sequencing,
733 enrichment was calculated by comparing clonotype UMI counts in stimulation conditions versus
734 baseline/unstimulated with a pseudocount of 1 for clonotypes that were absent from the baseline
735 sampling. Proliferation assay data was merged with the 10x data based on shared TCRB clonotypes.

736

737 TCR repertoires were explored using the tidyverse package (79) to aggregate and summarise data.
738 Diversity was calculated as Shannon's Entropy (80) as implemented by the entropart package (81).
739 Repertoire features were visualised with ggvenn [<https://CRAN.R-project.org/package=ggvenn>], circos
740 (82), ggpubr [<https://CRAN.R-project.org/package=ggpubr>] and ggsci [[https://CRAN.R-](https://CRAN.R-project.org/package=ggsci)
741 [project.org/package=ggsci](https://CRAN.R-project.org/package=ggsci)].

742

743 To annotate previously reported SARS-CoV-2 specific T cells, TCRBs reported to bind SARS-CoV-2
744 epitopes were obtained from two public resources; immuneCODE MIRA (release 002.2) (83) and
745 VDJdb (v2021-09-05) (84). TCRB clonotype labels were reformatted for consistency and clonotypes
746 were annotated based on shared clonotype labels between the databases and dataset.

747

748 **Statistical Analysis**

749

750 All column graphs are presented as medians with inter-quartile ranges. Mann-Whitney non-parametric
751 test was used to compare unpaired groups and Pearson's correlation was used to analyse statistical
752 relationships between continuous variables, employing Prism 9.0 software (GraphPad, La Jolla, CA,
753 USA). RStudio version 1.2.1335 was used to generate PCA graphs. *p* values <0.05 were considered
754 significant (*<0.05, **<0.01, ***<0.001, and ****<0.0001).

755

756 **Data availability**

757

758 Single-cell RNA transcriptomic and TCR sequences including codes and raw data has been deposited
759 to NCBI GEO database, accession number GSE198281. Novel SARS-CoV-2 specific TCR sequences
760 described in our study will be deposited into VdJdB database.

761

RBD-specific memory CD4 T cells

762 **SUPPLEMENTARY DATA**

763

764 Supplementary Table 1 - ADAPT study patient characteristics. Age, gender, ethnicity, and severity at
765 month 3 and 8 post-infection.

766 Supplementary Table 2 - Peptide pools: SN (spike non-RBD), SR (spike RBD), NP (Nucleocapsid
767 protein).

768 Supplementary Figure 1 - Cell trace violet (CTV) 7-day proliferation assay.

769 Supplementary Figure 2 - CD39+ antigen-specific Treg responses.

770 Supplementary Figure 3 - Cell sorting for single-cell transcriptomics.

771 Supplementary Figure 4 - Diversity of SARS-CoV-2 specific TCR clonotypes.

RBD-specific memory CD4 T cells

772 REFERENCES

773

- 774 1. C. H. Hansen, D. Michlmayr, S. M. Gubbels, K. Mølbak, S. Ethelberg, Assessment of
775 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in
776 Denmark in 2020: a population-level observational study. *Lancet* **397**, 1204-1212 (2021).
- 777 2. H. N. Altarawneh, H. Chemaitelly, M. R. Hasan, H. H. Ayoub, S. Qassim, S. AlMukdad, P.
778 Coyle, H. M. Yassine, H. A. Al-Khatib, F. M. Benslimane, Z. Al-Kanaani, E. Al-Kuwari, A.
779 Jeremijenko, A. H. Kaleeckal, A. N. Latif, R. M. Shaik, H. F. Abdul-Rahim, G. K. Nasrallah,
780 M. G. Al-Kuwari, A. A. Butt, H. E. Al-Romaihi, M. H. Al-Thani, A. Al-Khal, R. Bertollini, P.
781 Tang, L. J. Abu-Raddad, Protection against the Omicron Variant from Previous SARS-CoV-2
782 Infection. *New England Journal of Medicine* **386**, 1288-1290 (2022).
- 783 3. A. Fontanet, S. Cauchemez, COVID-19 herd immunity: where are we? *Nat Rev Immunol*,
784 (2020).
- 785 4. G. J. Nabel, Designing tomorrow's vaccines. *N Engl J Med* **368**, 551-560 (2013).
- 786 5. S. Crotty, Follicular helper CD4 T cells (TFH). *Annu Rev Immunol* **29**, 621-663 (2011).
- 787 6. M. M. Painter, D. Mathew, R. R. Goel, S. A. Apostolidis, A. Pattekar, O. Kuthuru, A. E.
788 Baxter, R. S. Herati, D. A. Oldridge, S. Gouma, P. Hicks, S. Dysinger, K. A. Lundgreen, L.
789 Kuri-Cervantes, S. Adamski, A. Hicks, S. Korte, J. R. Giles, M. E. Weirick, C. M. McAllister,
790 J. Dougherty, S. Long, K. D'Andrea, J. T. Hamilton, M. R. Betts, P. Bates, S. E. Hensley, A.
791 Grifoni, D. Weiskopf, A. Sette, A. R. Greenplate, E. J. Wherry, Rapid induction of antigen-
792 specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-
793 CoV-2 mRNA vaccination. *Immunity* **54**, 2133-2142 e2133 (2021).
- 794 7. J. J. Zaunders, W. B. Dyer, M. L. Munier, S. Ip, J. Liu, E. Amyes, W. Rawlinson, R. De Rose,
795 S. J. Kent, J. S. Sullivan, D. A. Cooper, A. D. Kelleher, CD127+CCR5+CD38+++ CD4+ Th1
796 effector cells are an early component of the primary immune response to vaccinia virus and
797 precede development of interleukin-2+ memory CD4+ T cells. *J Virol* **80**, 10151-10161 (2006).
- 798 8. C. M. Munier, D. van Bockel, M. Bailey, S. Ip, Y. Xu, S. Alcantara, S. M. Liu, G. Denyer, W.
799 Kaplan, P. S. group, K. Suzuki, N. Croft, A. Purcell, D. Tschärke, D. A. Cooper, S. J. Kent, J. J.
800 Zaunders, A. D. Kelleher, The primary immune response to Vaccinia virus vaccination includes
801 cells with a distinct cytotoxic effector CD4 T-cell phenotype. *Vaccine* **34**, 5251-5261 (2016).
- 802 9. E. Hammarlund, M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M.
803 Hanifin, M. K. Slifka, Duration of antiviral immunity after smallpox vaccination. *Nat Med* **9**,
804 1131-1137 (2003).
- 805 10. P. C. Doherty, J. P. Christensen, Accessing complexity: the dynamics of virus-specific T cell
806 responses. *Annu Rev Immunol* **18**, 561-592 (2000).
- 807 11. J. Zaunders, D. van Bockel, Innate and Adaptive Immunity in Long-Term Non-Progression in
808 HIV Disease. *Front Immunol* **4**, 95 (2013).
- 809 12. J. A. Juno, H. X. Tan, W. S. Lee, A. Reynaldi, H. G. Kelly, K. Wragg, R. Esterbauer, H. E.
810 Kent, C. J. Batten, F. L. Mordant, N. A. Gherardin, P. Pymm, M. H. Dietrich, N. E. Scott, W.
811 H. Tham, D. I. Godfrey, K. Subbarao, M. P. Davenport, S. J. Kent, A. K. Wheatley, Humoral
812 and circulating follicular helper T cell responses in recovered patients with COVID-19. *Nat*
813 *Med* **26**, 1428-1434 (2020).
- 814 13. A. Grifoni, D. Weiskopf, S. I. Ramirez, J. Mateus, J. M. Dan, C. R. Moderbacher, S. A.
815 Rawlings, A. Sutherland, L. Premkumar, R. S. Jadi, D. Marrama, A. M. de Silva, A. Frazier, A.
816 F. Carlin, J. A. Greenbaum, B. Peters, F. Krammer, D. M. Smith, S. Crotty, A. Sette, Targets of
817 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
818 Unexposed Individuals. *Cell* **181**, 1489-1501 e1415 (2020).
- 819 14. L. Ni, F. Ye, M. L. Cheng, Y. Feng, Y. Q. Deng, H. Zhao, P. Wei, J. Ge, M. Gou, X. Li, L. Sun,
820 T. Cao, P. Wang, C. Zhou, R. Zhang, P. Liang, H. Guo, X. Wang, C. F. Qin, F. Chen, C. Dong,

RBD-specific memory CD4 T cells

- 821 Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
822 Convalescent Individuals. *Immunity* **52**, 971-977 e973 (2020).
- 823 15. D. Weiskopf, K. S. Schmitz, M. P. Raadsen, A. Grifoni, N. M. A. Okba, H. Endeman, J. P. C.
824 van den Akker, R. Molenkamp, M. P. G. Koopmans, E. C. M. van Gorp, B. L. Haagmans, R. L.
825 de Swart, A. Sette, R. D. de Vries, Phenotype and kinetics of SARS-CoV-2-specific T cells in
826 COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol* **5**, (2020).
- 827 16. J. Braun, L. Loyal, M. Frensch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M.
828 Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold, L. Henze, R. Lauster, M. A. Mall,
829 K. Beyer, J. Rohmel, S. Voigt, J. Schmitz, S. Miltenyi, I. Demuth, M. A. Muller, A. Hocke, M.
830 Witzernath, N. Suttorp, F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V. M. Corman, C.
831 Giesecke-Thiel, L. E. Sander, A. Thiel, SARS-CoV-2-reactive T cells in healthy donors and
832 patients with COVID-19. *Nature*, (2020).
- 833 17. J. H. Jung, M. S. Rha, M. Sa, H. K. Choi, J. H. Jeon, H. Seok, D. W. Park, S. H. Park, H. W.
834 Jeong, W. S. Choi, E. C. Shin, SARS-CoV-2-specific T cell memory is sustained in COVID-19
835 convalescent patients for 10 months with successful development of stem cell-like memory T
836 cells. *Nat Commun* **12**, 4043 (2021).
- 837 18. J. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I. Ramirez, S.
838 Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F. Krammer, V. Simon,
839 E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette, S. Crotty, Immunological memory to
840 SARS-CoV-2 assessed for up to eight months after infection. *bioRxiv*, (2020).
- 841 19. J. J. Zaunders, M. L. Munier, N. Seddiki, S. Pett, S. Ip, M. Bailey, Y. Xu, K. Brown, W. B.
842 Dyer, M. Kim, R. de Rose, S. J. Kent, L. Jiang, S. N. Breit, S. Emery, A. L. Cunningham, D. A.
843 Cooper, A. D. Kelleher, High levels of human antigen-specific CD4+ T cells in peripheral
844 blood revealed by stimulated coexpression of CD25 and CD134 (OX40). *J Immunol* **183**, 2827-
845 2836 (2009).
- 846 20. J. S. Low, D. Vaqueirinho, F. Mele, M. Foglierini, J. Jerak, M. Perotti, D. Jarrossay, S. Jovic, L.
847 Perez, R. Cacciatore, T. Terrot, A. F. Pellanda, M. Biggiogero, C. Garzoni, P. Ferrari, A.
848 Ceschi, A. Lanzavecchia, F. Sallusto, A. Cassotta, Clonal analysis of immunodominance and
849 cross-reactivity of the CD4 T cell response to SARS-CoV-2. *Science* **372**, 1336-1341 (2021).
- 850 21. M. E. Schmidt, S. M. Varga, The CD8 T Cell Response to Respiratory Virus Infections. *Front*
851 *Immunol* **9**, 678 (2018).
- 852 22. M. S. Rha, E. C. Shin, Activation or exhaustion of CD8(+) T cells in patients with COVID-19.
853 *Cell Mol Immunol* **18**, 2325-2333 (2021).
- 854 23. A. Kusnadi, C. Ramirez-Suastegui, V. Fajardo, S. J. Chee, B. J. Meckiff, H. Simon, E. Pelosi,
855 G. Seumo, F. Ay, P. Vijayanand, C. H. Ottensmeier, Severely ill COVID-19 patients display
856 impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells. *Sci Immunol* **6**, (2021).
- 857 24. E. Gimenez, E. Albert, I. Torres, M. J. Remigia, M. J. Alcaraz, M. J. Galindo, M. L. Blasco, C.
858 Solano, M. J. Forner, J. Redon, J. Signes-Costa, D. Navarro, SARS-CoV-2-reactive interferon-
859 gamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019. *J Med*
860 *Virol* **93**, 375-382 (2021).
- 861 25. K. E. Lineburg, E. J. Grant, S. Swaminathan, D. S. M. Chatzileontiadou, C. Szeto, H. Sloane,
862 A. Panikkar, J. Raju, P. Crooks, S. Rehan, A. T. Nguyen, L. Lekieffre, M. A. Neller, Z. W. M.
863 Tong, D. Jayasinghe, K. Y. Chew, C. A. Lobos, H. Halim, J. M. Burrows, A. Riboldi-
864 Tunnicliffe, W. Chen, L. D'Orsogna, R. Khanna, K. R. Short, C. Smith, S. Gras, CD8(+) T cells
865 specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective
866 seasonal coronaviruses. *Immunity* **54**, 1055-1065 e1055 (2021).
- 867 26. I. Schulien, J. Kemming, V. Oberhardt, K. Wild, L. M. Seidel, S. Killmer, Sagar, F. Daul, M.
868 Salvat Lago, A. Decker, H. Luxenburger, B. Binder, D. Bettinger, O. Sogukpinar, S. Rieg, M.
869 Panning, D. Huzly, M. Schwemmler, G. Kochs, C. F. Waller, A. Nieters, D. Duerschmied, F.

RBD-specific memory CD4 T cells

- 870 Emmerich, H. E. Mei, A. R. Schulz, S. Llewellyn-Lacey, D. A. Price, T. Boettler, B. Bengsch,
871 R. Thimme, M. Hofmann, C. Neumann-Haefelin, Characterization of pre-existing and induced
872 SARS-CoV-2-specific CD8(+) T cells. *Nat Med* **27**, 78-85 (2021).
- 873 27. T. H. O. Nguyen, L. C. Rowntree, J. Petersen, B. Y. Chua, L. Hensen, L. Kedzierski, C. E. van
874 de Sandt, P. Chaurasia, H. X. Tan, J. R. Habel, W. Zhang, L. F. Allen, L. Earnest, K. Y. Mak, J.
875 A. Juno, K. Wragg, F. L. Mordant, F. Amanat, F. Krammer, N. A. Mifsud, D. L. Doolan, K. L.
876 Flanagan, S. Sonda, J. Kaur, L. M. Wakim, G. P. Westall, F. James, E. Mouhtouris, C. L.
877 Gordon, N. E. Holmes, O. C. Smibert, J. A. Trubiano, A. C. Cheng, P. Harcourt, P. Clifton, J.
878 C. Crawford, P. G. Thomas, A. K. Wheatley, S. J. Kent, J. Rossjohn, J. Torresi, K. Kedzierska,
879 CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display
880 high naive precursor frequency and TCR promiscuity. *Immunity* **54**, 1066-1082 e1065 (2021).
- 881 28. F. Tea, A. Ospina Stella, A. Aggarwal, D. Ross Darley, D. Pilli, D. Vitale, V. Merheb, F. X. Z.
882 Lee, P. Cunningham, G. J. Walker, C. Fichter, D. A. Brown, W. D. Rawlinson, S. R. Isaacs, V.
883 Mathivanan, M. Hoffmann, S. Pohlman, O. Mazigi, D. Christ, D. E. Dwyer, R. J. Rockett, V.
884 Sintchenko, V. C. Hoad, D. O. Irving, G. J. Dore, I. B. Gosbell, A. D. Kelleher, G. V.
885 Matthews, F. Brilot, S. G. Turville, SARS-CoV-2 neutralizing antibodies: Longevity, breadth,
886 and evasion by emerging viral variants. *PLoS medicine* **18**, e1003656 (2021).
- 887 29. M. Wolf, J. Kuball, W. Y. Ho, H. Nguyen, T. J. Manley, M. Bleakley, P. D. Greenberg,
888 Activation-induced expression of CD137 permits detection, isolation, and expansion of the full
889 repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope
890 specificities. *Blood* **110**, 201-210 (2007).
- 891 30. N. Seddiki, L. Cook, D. C. Hsu, C. Phetsouphanh, K. Brown, Y. Xu, S. J. Kerr, D. A. Cooper,
892 C. M. Munier, S. Pett, J. Ananworanich, J. Zaunders, A. D. Kelleher, Human antigen-specific
893 CD4(+) CD25(+) CD134(+) CD39(+) T cells are enriched for regulatory T cells and comprise a
894 substantial proportion of recall responses. *Eur J Immunol* **44**, 1644-1661 (2014).
- 895 31. H. Balachandran, C. Phetsouphanh, D. Agapiou, A. Adhikari, C. Rodrigo, M. Hammoud, L. B.
896 Shrestha, E. Keoshkerian, M. Gupta, S. Turville, D. Christ, C. King, S. C. Sasson, A. Bartlett,
897 B. Grubor-Bauk, W. Rawlinson, A. Aggarwal, A. O. Stella, V. Klemm, M. M. Mina, J. J. Post,
898 B. Hudson, N. Gilroy, P. Konecny, G. Ahlenstiel, D. E. Dwyer, T. C. Sorrell, A. Kelleher, N.
899 Tedla, A. R. Lloyd, M. Martinello, R. A. Bull, C. S. Group, Maintenance of broad neutralizing
900 antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific
901 CD4+ T cell responses. *Cell reports* **38**, 110345 (2022).
- 902 32. D. S. Houry, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao,
903 S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly predictive of
904 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
- 905 33. J. M. Dan, J. Mateus, Y. Kato, K. M. Hastie, E. D. Yu, C. E. Faliti, A. Grifoni, S. I. Ramirez, S.
906 Haupt, A. Frazier, C. Nakao, V. Rayaprolu, S. A. Rawlings, B. Peters, F. Krammer, V. Simon,
907 E. O. Saphire, D. M. Smith, D. Weiskopf, A. Sette, S. Crotty, Immunological memory to
908 SARS-CoV-2 assessed for up to 8 months after infection. *Science* **371**, (2021).
- 909 34. J. Mateus, A. Grifoni, A. Tarke, J. Sidney, S. I. Ramirez, J. M. Dan, Z. C. Burger, S. A.
910 Rawlings, D. M. Smith, E. Phillips, S. Mallal, M. Lammers, P. Rubiro, L. Quiambao, A.
911 Sutherland, E. D. Yu, R. da Silva Antunes, J. Greenbaum, A. Frazier, A. J. Markmann, L.
912 Premkumar, A. de Silva, B. Peters, S. Crotty, A. Sette, D. Weiskopf, Selective and cross-
913 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science*, (2020).
- 914 35. B. J. Meckiff, C. Ramirez-Suastegui, V. Fajardo, S. J. Chee, A. Kusnadi, H. Simon, A. Grifoni,
915 E. Pelosi, D. Weiskopf, A. Sette, F. Ay, G. Seumois, C. H. Ottensmeier, P. Vijayanand, Single-
916 Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 (+) T Cells. *SSRN*, 3641939
917 (2020).

RBD-specific memory CD4 T cells

- 918 36. J. J. Zaunders, S. Ip, M. L. Munier, D. E. Kaufmann, K. Suzuki, C. Breton, S. C. Sasson, N.
919 Seddiki, K. Koelsch, A. Landay, P. Grey, R. Finlayson, J. Kaldor, E. S. Rosenberg, B. D.
920 Walker, B. Fazekas de St Groth, D. A. Cooper, A. D. Kelleher, Infection of CD127+
921 (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of
922 antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. *J*
923 *Virol* **80**, 10162-10172 (2006).
- 924 37. D. E. Kaufmann, D. G. Kavanagh, F. Pereyra, J. J. Zaunders, E. W. Mackey, T. Miura, S.
925 Palmer, M. Brockman, A. Rathod, A. Piechocka-Trocha, B. Baker, B. Zhu, S. Le Gall, M. T.
926 Waring, R. Ahern, K. Moss, A. D. Kelleher, J. M. Coffin, G. J. Freeman, E. S. Rosenberg, B. D.
927 Walker, Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease
928 progression and defines a reversible immune dysfunction. *Nat Immunol* **8**, 1246-1254 (2007).
- 929 38. S. Boppana, K. Qin, J. K. Files, R. M. Russell, R. Stoltz, F. Bibollet-Ruche, A. Bansal, N.
930 Erdmann, B. H. Hahn, P. A. Goepfert, SARS-CoV-2-specific circulating T follicular helper
931 cells correlate with neutralizing antibodies and increase during early convalescence. *PLoS*
932 *Pathog* **17**, e1009761 (2021).
- 933 39. A. Tarke, J. Sidney, C. K. Kidd, J. M. Dan, S. I. Ramirez, E. D. Yu, J. Mateus, R. da Silva
934 Antunes, E. Moore, P. Rubiro, N. Methot, E. Phillips, S. Mallal, A. Frazier, S. A. Rawlings, J.
935 A. Greenbaum, B. Peters, D. M. Smith, S. Crotty, D. Weiskopf, A. Grifoni, A. Sette,
936 Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2
937 epitopes in COVID-19 cases. *Cell Rep Med* **2**, 100204 (2021).
- 938 40. W. J. Hey-Nguyen, Y. Xu, C. F. Pearson, M. Bailey, K. Suzuki, R. Tantau, S. Obeid, B. Milner,
939 A. Field, A. Carr, M. Bloch, D. A. Cooper, A. D. Kelleher, J. J. Zaunders, K. K. Koelsch,
940 Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using
941 Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy. *AIDS Res Hum*
942 *Retroviruses* **33**, 648-657 (2017).
- 943 41. H. Law, M. Mach, A. Howe, S. Obeid, B. Milner, C. Carey, M. Elfis, B. Fsadni, K.
944 Ognenovska, T. G. Phan, D. Carey, Y. Xu, V. Venturi, J. Zaunders, A. D. Kelleher, C. M. L.
945 Munier, Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza
946 vaccination immune response. *iScience* **25**, 103656 (2022).
- 947 42. Y. Xu, C. Phetsouphanh, K. Suzuki, A. Aggrawal, S. Graff-Dubois, M. Roche, M. Bailey, S.
948 Alcantara, K. Cashin, R. Sivasubramaniam, K. K. Koelsch, B. Autran, R. Harvey, P. R. Gorry,
949 A. Moris, D. A. Cooper, S. Turville, S. J. Kent, A. D. Kelleher, J. Zaunders, HIV-1 and SIV
950 Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T
951 Follicular Helper Cells. *Front Immunol* **8**, 376 (2017).
- 952 43. C. Phetsouphanh, Y. Xu, J. Amin, N. Seddiki, F. Procopio, R. P. Sekaly, J. J. Zaunders, A. D.
953 Kelleher, Characterization of Transcription Factor Phenotypes within Antigen-Specific CD4+ T
954 Cells Using Qualitative Multiplex Single-Cell RT-PCR. *PLoS One* **8**, e74946 (2013).
- 955 44. R. Morita, N. Schmitt, S. E. Bentebibel, R. Ranganathan, L. Bourdery, G. Zurawski, E. Foucat,
956 M. Dullaers, S. Oh, N. Sabzghabaei, E. M. Lavecchio, M. Punaro, V. Pascual, J. Banachereau,
957 H. Ueno, Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and
958 contain specific subsets that differentially support antibody secretion. *Immunity* **34**, 108-121
959 (2011).
- 960 45. J. J. Zaunders, W. B. Dyer, B. Wang, M. L. Munier, M. Miranda-Saksena, R. Newton, J.
961 Moore, C. R. Mackay, D. A. Cooper, N. K. Saksena, A. D. Kelleher, Identification of
962 circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an
963 HIV-1 long-term nonprogressor and in CMV infection. *Blood* **103**, 2238-2247 (2004).
- 964 46. V. Appay, J. J. Zaunders, L. Papagno, J. Sutton, A. Jaramillo, A. Waters, P. Easterbrook, P.
965 Grey, D. Smith, A. J. McMichael, D. A. Cooper, S. L. Rowland-Jones, A. D. Kelleher,
966 Characterization of CD4(+) CTLs ex vivo. *J Immunol* **168**, 5954-5958 (2002).

RBD-specific memory CD4 T cells

- 967 47. C. Phetsouphanh, D. Aldridge, E. Marchi, C. M. L. Munier, J. Meyerowitz, L. Murray, C. Van
968 Vuuren, D. Goedhals, S. Fidler, A. Kelleher, P. Klenerman, J. Frater, Maintenance of
969 Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers. *Front Immunol* **10**, 1844
970 (2019).
- 971 48. J. A. Juno, D. van Bockel, S. J. Kent, A. D. Kelleher, J. J. Zaunders, C. M. Munier, Cytotoxic
972 CD4 T Cells-Friend or Foe during Viral Infection? *Front Immunol* **8**, 19 (2017).
- 973 49. I. Thevarajan, T. H. O. Nguyen, M. Koutsakos, J. Druce, L. Caly, C. E. van de Sandt, X. Jia, S.
974 Nicholson, M. Catton, B. Cowie, S. Y. C. Tong, S. R. Lewin, K. Kedzierska, Breadth of
975 concomitant immune responses prior to patient recovery: a case report of non-severe COVID-
976 19. *Nat Med* **26**, 453-455 (2020).
- 977 50. P. Anderson, C. Nagler-Anderson, C. O'Brien, H. Levine, S. Watkins, H. S. Slayter, M. L. Blue,
978 S. F. Schlossman, A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-
979 associated protein defines a subpopulation of CD8+ T lymphocytes. *J Immunol* **144**, 574-582.
980 (1990).
- 981 51. J. Y. Zhang, X. M. Wang, X. Xing, Z. Xu, C. Zhang, J. W. Song, X. Fan, P. Xia, J. L. Fu, S. Y.
982 Wang, R. N. Xu, X. P. Dai, L. Shi, L. Huang, T. J. Jiang, M. Shi, Y. Zhang, A. Zumla, M.
983 Maeurer, F. Bai, F. S. Wang, Single-cell landscape of immunological responses in patients with
984 COVID-19. *Nat Immunol* **21**, 1107-1118 (2020).
- 985 52. J. A. Jaimes, J. K. Millet, G. R. Whittaker, Proteolytic Cleavage of the SARS-CoV-2 Spike
986 Protein and the Role of the Novel S1/S2 Site. *iScience* **23**, 101212 (2020).
- 987 53. M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herrler, S. Erichsen, T. S.
988 Schiergens, G. Herrler, N. H. Wu, A. Nitsche, M. A. Muller, C. Drosten, S. Pohlmann, SARS-
989 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
990 Protease Inhibitor. *Cell* **181**, 271-280 e278 (2020).
- 991 54. R. Essalmani, J. Jain, D. Susan-Resiga, U. Andreo, A. Evagelidis, R. M. Derbali, D. N. Huynh,
992 F. Dallaire, M. Laporte, A. Delpal, P. Sutto-Ortiz, B. Coutard, C. Mapa, K. Wilcoxon, E.
993 Decroly, T. Nq Pham, E. A. Cohen, N. G. Seidah, Distinctive Roles of Furin and TMPRSS2 in
994 SARS-CoV-2 Infectivity. *J Virol*, e0012822 (2022).
- 995 55. S. M. Russell, F. Y. Liew, T cells primed by influenza virion internal components can cooperate
996 in the antibody response to haemagglutinin. *Nature* **280**, 147-148 (1979).
- 997 56. P. A. Scherle, W. Gerhard, Functional analysis of influenza-specific helper T cell clones in
998 vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to
999 hemagglutinin. *J Exp Med* **164**, 1114-1128 (1986).
- 1000 57. A. Sette, M. Moutaftsi, J. Moyron-Quiroz, M. M. McCausland, D. H. Davies, R. J. Johnston, B.
1001 Peters, M. Ralfi-El-Idrissi Benhnia, J. Hoffmann, H. P. Su, K. Singh, D. N. Garboczi, S. Head,
1002 H. Grey, P. L. Felgner, S. Crotty, Selective CD4+ T cell help for antibody responses to a large
1003 viral pathogen: deterministic linkage of specificities. *Immunity* **28**, 847-858 (2008).
- 1004 58. T. Sztain, S. H. Ahn, A. T. Bogetti, L. Casalino, J. A. Goldsmith, E. Seitz, R. S. McCool, F. L.
1005 Kearns, F. Acosta-Reyes, S. Maji, G. Mashayekhi, J. A. McCammon, A. Ourmazd, J. Frank, J.
1006 S. McLellan, L. T. Chong, R. E. Amaro, A glycan gate controls opening of the SARS-CoV-2
1007 spike protein. *bioRxiv*, (2021).
- 1008 59. B. Li, A. Deng, K. Li, Y. Hu, Z. Li, Y. Shi, Q. Xiong, Z. Liu, Q. Guo, L. Zou, H. Zhang, M.
1009 Zhang, F. Ouyang, J. Su, W. Su, J. Xu, H. Lin, J. Sun, J. Peng, H. Jiang, P. Zhou, T. Hu, M.
1010 Luo, Y. Zhang, H. Zheng, J. Xiao, T. Liu, M. Tan, R. Che, H. Zeng, Z. Zheng, Y. Huang, J. Yu,
1011 L. Yi, J. Wu, J. Chen, H. Zhong, X. Deng, M. Kang, O. G. Pybus, M. Hall, K. A. Lythgoe, Y.
1012 Li, J. Yuan, J. He, J. Lu, Viral infection and transmission in a large, well-traced outbreak caused
1013 by the SARS-CoV-2 Delta variant. *Nature communications* **13**, 460 (2022).

RBD-specific memory CD4 T cells

- 1014 60. A. Grifoni, J. Sidney, R. Vita, B. Peters, S. Crotty, D. Weiskopf, A. Sette, SARS-CoV-2 human
1015 T cell epitopes: Adaptive immune response against COVID-19. *Cell Host Microbe* **29**, 1076-
1016 1092 (2021).
- 1017 61. D. R. Darley, G. J. Dore, L. Cysique, K. A. Wilhelm, D. Andresen, K. Tonga, E. Stone, A.
1018 Byrne, M. Plit, J. Masters, H. Tang, B. Brew, P. Cunningham, A. Kelleher, G. V. Matthews,
1019 Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2
1020 infection. *The Medical Journal of Australia* **214**, 279-280 (2021).
- 1021 62. C. Phetsouphanh, D. R. Darley, D. B. Wilson, A. Howe, C. M. L. Munier, S. K. Patel, J. A.
1022 Juno, L. M. Burrell, S. J. Kent, G. J. Dore, A. D. Kelleher, G. V. Matthews, Immunological
1023 dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.
1024 *Nat Immunol* **23**, 210-216 (2022).
- 1025 63. R. Rouet, O. Mazigi, G. J. Walker, D. B. Langley, M. Sobti, P. Schofield, H. Lenthall, J.
1026 Jackson, S. Ubiparipovic, J. Y. Henry, A. Abayasingam, D. Burnett, A. Kelleher, R. Brink, R.
1027 A. Bull, S. Turville, A. G. Stewart, C. C. Goodnow, W. D. Rawlinson, D. Christ, Potent SARS-
1028 CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. *MAbs*
1029 **13**, 1922134 (2021).
- 1030 64. J. Zaunders, C. M. L. Munier, H. M. McGuire, H. Law, A. Howe, Y. Xu, B. F. de St Groth, P.
1031 Schofield, D. Christ, B. Milner, S. Obeid, W. B. Dyer, N. K. Saksena, A. D. Kelleher, Mapping
1032 the extent of heterogeneity of human CCR5+ CD4+ T cells in peripheral blood and lymph
1033 nodes. *AIDS* **34**, 833-848 (2020).
- 1034 65. D. C. Hsu, J. J. Zaunders, M. Plit, C. Leeman, S. Ip, T. Iampornsin, S. L. Pett, M. Bailey, J.
1035 Amin, S. Ubolyam, A. Avihingsanon, J. Ananworanich, K. Ruxrungtham, D. A. Cooper, A. D.
1036 Kelleher, A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison
1037 with existing assays. *Tuberculosis (Edinb)* **92**, 321-327 (2012).
- 1038 66. J. Zaunders, W. Dyer, M. Churchill, C. Munier, P. Cunningham, K. Suzuki, K. McBride, W.
1039 Hey-Nguyen, K. Koelsch, B. Wang, B. Hiener, S. Palmer, P. Gorry, M. Bailey, Y. Xu, M.
1040 Danta, N. Seddiki, D. Cooper, N. Saksena, J. Sullivan, S. Riminton, J. Learmont, A. Kelleher,
1041 Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an
1042 elite controller with CCR5 Δ 32 heterozygous and HLA-B57 genotype. *Journal of Virus*
1043 *Eradication* **5**, 73-83 (2019).
- 1044 67. A. Aggarwal, A. Stella, G. Walker, A. Akerman, Esneau C, V. Milogiannakis, D. Burnett, S.
1045 McAllery, M. Ruiz Silva, Y. Lu, C. Foster, F. Brilot, A. Pillay, S. van Hal, S. Mathivanan, C.
1046 Fichter, A. Kindinger, A. Carey Hoppe, C. Munier, S. Amatayakul-Chantler, N. Roth, G.
1047 Coppola, G. Symonds, P. Schofield, J. Jackson, H. Lenthall, J. Henry, C. Mazigi, H.-M. Jäck,
1048 M. Davenport, D. Darley, G. Matthews, D. Houry, D. Cromer, C. Goodnow, D. Christ, R.
1049 Robosa, D. Starck, N. Bartlett, W. Rawlinson, A. Kelleher, S. Turville, Platform for isolation
1050 and characterization of SARS-CoV-2 variants enables rapid characterisation of Omicron in
1051 Australia. *Nature Microbiology* **In press**, (2022).
- 1052 68. M. Stoeckius, C. Hafemeister, W. Stephenson, B. Houck-Loomis, P. K. Chattopadhyay, H.
1053 Swerdlow, R. Satija, P. Smibert, Simultaneous epitope and transcriptome measurement in single
1054 cells. *Nat Methods* **14**, 865-868 (2017).
- 1055 69. T. Stuart, A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck, 3rd, Y. Hao, M.
1056 Stoeckius, P. Smibert, R. Satija, Comprehensive Integration of Single-Cell Data. *Cell* **177**,
1057 1888-1902 e1821 (2019).
- 1058 70. C. Hafemeister, R. Satija, Normalization and variance stabilization of single-cell RNA-seq data
1059 using regularized negative binomial regression. *Genome Biol* **20**, 296 (2019).
- 1060 71. A. T. Lun, D. J. McCarthy, J. C. Marioni, A step-by-step workflow for low-level analysis of
1061 single-cell RNA-seq data with Bioconductor. *F1000Res* **5**, 2122 (2016).

RBD-specific memory CD4 T cells

- 1062 72. D. J. McCarthy, K. R. Campbell, A. T. Lun, Q. F. Wills, Scater: pre-processing, quality control,
1063 normalization and visualization of single-cell RNA-seq data in R. *Bioinformatics* **33**, 1179-1186
1064 (2017).
- 1065 73. C. W. Law, Y. Chen, W. Shi, G. K. Smyth, voom: Precision weights unlock linear model
1066 analysis tools for RNA-seq read counts. *Genome Biol* **15**, R29 (2014).
- 1067 74. J. Massey, K. Jackson, M. Singh, B. Hughes, B. Withers, C. Ford, M. M. Khoo, K. K.
1068 Hendrawan, J. J. Zaunders, B. Charmeteau-De Muylder, R. Cheynier, F. Luciani, D. D. Ma, J.
1069 Moore, I. Sutton, Haematopoietic Stem Cell Transplantation Results in Extensive Remodelling
1070 of the Clonal T Cell Repertoire in Multiple Sclerosis. *Frontiers in Immunology* **13**, (2022).
- 1071 75. J. A. Vander Heiden, G. Yaari, M. Uduman, J. N. H. Stern, K. C. O'Connor, D. A. Hafler, F.
1072 Vigneault, S. H. Kleinstei, pRESTO: a toolkit for processing high-throughput sequencing raw
1073 reads of lymphocyte receptor repertoires. *Bioinformatics* **30**, 1930-1932 (2014).
- 1074 76. J. Ye, N. Ma, T. L. Madden, J. M. Ostell, IgBLAST: an immunoglobulin variable domain
1075 sequence analysis tool. *Nucleic Acids Res* **41**, W34-40 (2013).
- 1076 77. N. T. Gupta, J. A. Vander Heiden, M. Uduman, D. Gadala-Maria, G. Yaari, S. H. Kleinstei,
1077 Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing
1078 data. *Bioinformatics* **31**, 3356-3358 (2015).
- 1079 78. Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck, 3rd, S. Zheng, A. Butler, M. J. Lee, A. J.
1080 Wilk, C. Darby, M. Zager, P. Hoffman, M. Stoeckius, E. Papalexi, E. P. Mimitou, J. Jain, A.
1081 Srivastava, T. Stuart, L. M. Fleming, B. Yeung, A. J. Rogers, J. M. McElrath, C. A. Blish, R.
1082 Gottardo, P. Smibert, R. Satija, Integrated analysis of multimodal single-cell data. *Cell* **184**,
1083 3573-3587.e3529 (2021).
- 1084 79. H. Wickham, M. Averick, J. Bryan, W. Chang, L. McGowan, R. François, G. Grolemond, A.
1085 Hayes, L. Henry, J. Hester, M. Kuhn, T. Pedersen, E. Miller, S. Milton Bache, K. Müller, J.
1086 Ooms, D. Robinson, D. Seidel, V. Spinu, K. Takahashi, D. Vaughan, C. Wilke, K. Woo, H.
1087 Yutani, Welcome to the tidyverse. *Journal of Open Source Software* **4**, (2019).
- 1088 80. C. E. Shannon, A mathematical theory of communication. *The Bell System Technical Journal*
1089 **27**, 379-423 (1948).
- 1090 81. E. Marcon, B. Hérault, entropart: An R Package to Measure and Partition Diversity. *Journal of*
1091 *Statistical Software* **67**, 1 - 26 (2015).
- 1092 82. M. Krzywinski, J. Schein, I. Birol, J. Connors, R. Gascoyne, D. Horsman, S. J. Jones, M. A.
1093 Marra, Circos: an information aesthetic for comparative genomics. *Genome Res* **19**, 1639-1645
1094 (2009).
- 1095 83. S. Nolan, M. Vignali, M. Klinger, J. N. Dines, I. M. Kaplan, E. Svejnoha, T. Craft, K. Boland,
1096 M. Pesesky, R. M. Gittelman, T. M. Snyder, C. J. Gooley, S. Semprini, C. Cerchione, M.
1097 Mazza, O. M. Delmonte, K. Dobbs, G. Carreño-Tarragona, S. Barrio, V. Sambri, G. Martinelli,
1098 J. D. Goldman, J. R. Heath, L. D. Notarangelo, J. M. Carlson, J. Martinez-Lopez, H. S. Robins,
1099 A large-scale database of T-cell receptor beta (TCR β) sequences and binding associations from
1100 natural and synthetic exposure to SARS-CoV-2. *Res Sq*, (2020).
- 1101 84. D. V. Bagaev, R. M. A. Vroomans, J. Samir, U. Stervbo, C. Rius, G. Dolton, A. Greenshields-
1102 Watson, M. Attaf, E. S. Egorov, I. V. Zvyagin, N. Babel, D. K. Cole, A. J. Godkin, A. K.
1103 Sewell, C. Kesmir, D. M. Chudakov, F. Luciani, M. Shugay, VDJdb in 2019: database
1104 extension, new analysis infrastructure and a T-cell receptor motif compendium. *Nucleic Acids*
1105 *Research* **48**, D1057-D1062 (2019).
- 1106
1107
1108
1109
1110

RBD-specific memory CD4 T cells

1111 **ACKNOWLEDGMENTS**

1112

1113 The authors thank Bertha Fsadni, Sri Meka, Julie Jurczykuk and Kate Merlin at the St Vincent's
1114 Institute for Applied Medical Research-Clinical Trials Unit for their expertise in specimen processing
1115 and bio-banking. We thank Dr Emma Johansson Beves for assistance on the Cytex Aurora.

1116

1117 **Funding**

1118

1119 St Vincent's Clinic Foundation Grant (GVM, GJD, DD)

1120 Medical Research Future Fund Grant (ST, FB-T, TGP, JZ)

1121 National Health and Medical Research Council (NHMRC) Program Grant ID1149990 (ADK)

1122 NHMRC Fellowship ID1155678 (TGP)

1123 UNSW Cellular Genomics Futures Institute Seed Funding (WHK)

1124 Mrs. Janice Gibson and the Ernest Heine Family Foundation (PIC and TGP)

1125 Garvan Institute COVID Catalytic Grant (TGP)

1126 UNSW COVID-19 Rapid Response Research Initiative (TGP)

1127

1128 **Competing interests**

1129 The authors declare no competing interests

1130

1131 **Author contributions**

1132 Protocol design and clinical management: GVM, GJD, DD

1133 Experimental design and procedures: CP, WHK, KLJ, VK, AH, AAg, AAk, VM, AOS, RR, PS, MLK,
1134 HL, TD, MS, CMLM, MS, FB-T, ST, TGP, ADK, JZ

1135 Visualization: CP, WHK, KLJ, JZ

1136 Funding acquisition: GVM, GJD, DD, DC, ST, FB-T, TGP, PC, ADK, JZ

1137 Supervision: DC, ST, PC, GVM, PIC, TGP, ADK

1138 Writing – original draft: CP, WHK, KLJ, TGP, JZ


1139 Writing – review & editing: CP, WHK, KLJ, CMLM, ST, AAg, TGP, ADK, JZ

1140


1141

RBD-specific memory CD4 T cells


1142 Figure 1
1143 1A




1B



1144 1C




1D




1145
1146


1E



1F



1G




1147
1148

1149 **Figure 1- Proliferation of SARS-CoV-2 reactive CD4+ T cells correlate with antibodies.**


1150 (A) Representative dot plots of CD25+CD134+ co-expression on RBD-specific CD4+ T cells. (B) Frequency of
1151 RBD reactive CD4+ T cells in convalescent subjects (conv) compared to unexposed healthy controls (UHC). (C)
1152 Percentage of proliferating CD4+ T cells stimulated with RBD or Flu antigen. (D) Positive correlation between
1153 recall CD25+CD134+ CD4 response and 7 days of proliferation. (E) Correlation between spike IgG levels and
1154 RBD specific proliferation of CD4+ T cells. (F) Convalescent subjects with proliferated CD4+ T cells (>1%) are
1155 Ab high vs subjects without proliferation (<1%) are Ab low, based on combined IgG/IgM score. (G) Subjects
1156 with proliferated CD4+ T cells (>1%) have significantly higher neutralizing Ab titres (NT₅₀) vs subjects without
1157 proliferation (<1%). Data shown as medians with interquartile ranges. Two-tailed p values <0.05 were
1158 considered significant (*<0.05, **<0.01, ***<0.001, ****<0.0001). Mann-Whitney T tests were used for
1159 unpaired groups and Pearson's rho was used for correlations.

RBD-specific memory CD4 T cells

1160 Figure 2
2A



2B




2C

3 Month Neutralization Titre (NT₅₀)

	**	*	***	***
High 1	320	80	160	160
High 2	1280	320	320	640
High 3	1280	640	1280	1280
High 4	320	80	160	160
High 5	320	40	80	160
High 6	640	160	320	320
High 7	320	80	160	160
High 8	80	40	40	40
High 9	320	160	160	160
High 10	320	0	0	0
High 11	160	40	80	80
High 12	320	80	160	320
Low 1	20	0	0	0
Low 2	0	0	0	0
Low 3	20	0	0	0
Low 4	20	0	0	0
Low 5	40	0	0	0
Low 6	20	20	0	20
Low 7	40	0	0	0
Low 8	20	0	0	0
Low 9	0	0	0	0
Low 10	20	0	0	0
Low 11	0	0	0	0
Low 12	0	0	0	0

Ancestral Beta Gamma Delta

2D



1161


1162 **Figure 2- Higher neutralization breadth in Ab high group that decreases over time.**

1163 (A) Representative dot plot showing difference in neutralisation of Ab high (blue) and Ab body low
 1164 (groups) over time. (B) Reduction of neutralizing antibodies over time. 3M (3 months), 4M (4 months),
 1165 8M (8 months). (C) Increased neutralising breadth of Ab high group compared to antibody low. (D)
 1166 Decreased neutralization titre in Ab high group at 8-months post-infection but remain higher than Ab
 1167 low. Two-tailed p values <0.05 were considered significant (ns-not significant, *<0.05, **<0.01,
 1168 ***<0.001, ****<0.0001). Wilcoxon T tests were used for paired groups and Mann-Whitney used for
 1169 unpaired. Heatmap values shown as median neutralization titre.


1170

RBD-specific memory CD4 T cells

1171 Figure 3A




B




1172

1173

C



D



1174

1175

Figure 3- Higher frequencies of RBD-specific CD4+ T cells in Ab high group.

1176

(A) CD4 responses to influenza, spike, RBD and nucleoprotein (NP) at 3M and 8M post- infection. (B) Higher

1177

frequency of SARS-CoV-2 proliferative CD4 T cells in Ab high group compared to Ab low at 3M and 8M. (medians

1178

with interquartile ranges). (C) Representative UMAP of proliferated CD4 T cells: concatenated; ab high; and ab low.

1179

Red gates are regulatory-like cells present in Ab low subjects. (D) Regulatory-like Foxp3+ cells are higher in Ab low

1180

subjects (grey columns) compared with higher effector cells in Ab high subjects (black columns). The colour and

1181


number of horizontal bar graphs match with UMAP clusters. Two-tailed p values <0.05 were considered significant

1182


(ns-not significant, *<0.05, **<0.01, ***<0.001, ****<0.0001). Mann-Whitney T test used for unpaired samples.

RBD-specific memory CD4 T cells

1183 Figure 4A




B




1184

1185

C



D



1186

1187

1188

1189 **Figure 4- No difference in CD8 responses but presence of inhibitory receptors in Ab low subjects.**

1190 (A) No difference between CD8 in Ab high and Ab low groups. (B) Higher frequency of NP proliferative CD8 T

1191 cells in Ab high group compared to Ab low. 3M (3 months) and 8M (8 months). Data shown as medians with

1192 interquartile ranges. (C) Representative UMAP of proliferated CD8 T cells; concatenated, ab high and ab low.


1193 (D) Presence of an inhibitory phenotype within cells of Ab low subjects. Colour and number of horizontal bar

1194 graphs match with UMAP clusters. Black columns (Ab high) and grey columns (Ab low). Two-tailed p values

1195 <0.05 were considered significant (*<0.05, **<0.01). Mann-Whitney T test used for unpaired samples.

RBD-specific memory CD4 T cells

1196 Figure 5



1208


1209 **Figure 5- B and T cell parameters correlate with antibody response.**

1210 (A) Higher CD38+ B cell plasmablasts in Ab high group. (B) Elevated double negative (DN, IgD-CD127-) B
 1211 cells in Ab low group. Naïve (N, IgD+CD127-), non-switched memory (NSM, IgD+CD127+), switched
 1212 memory (SM, IgD-CD127+) B cells. Higher CXCR5 expression on CD4s (C), activation (CD38+HLA-DR+) on
 1213 CD4 (D) and CD8 (E), and CD4 effector memory cells (F) in Ab High compared to Ab low group. Data shown
 1214 as medians with interquartile ranges. (G) Higher naïve CD8+ T cells in Ab low group at both timepoints. SN
 1215 (spike), SR (RBD), NP (nucleoprotein). Two-tailed p values <0.05 were considered significant (*<0.05,
 1216 **<0.01, ***<0.001. Mann-Whitney T tests were used for unpaired groups.


1217

RBD-specific memory CD4 T cells

1218 Figure 5 (cont'd) **5H**



5I



1242 **Figure 5- (cont'd) B and T cell parameters correlate with antibody response.**

1243

1244 **(H)** B cell plasmablast, CXCR5+ CD4 T cells, activated CD4 and CD8 T cells, proliferative Spike and RBD-

1245 specific CD4 positively correlate with humoral response at 3 months post-infection (red box). **(I)** PCA clustering

1246 of Ab high and Ab low groups based on T and B cell parameters. Pearson's rho was used for correlations and


1247 adjusted *p* values shown with Benjamini-Hochberg correction used for multiple comparisons. Two-tailed *p*

1248 values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001).

1249

RBD-specific memory CD4 T cells


1250 Figure 6
1251



1252

RBD-specific memory CD4 T cells

1253 Figure 6 (cont'd)
1254



1255
1256

Figure 6- Single-cell RNAseq reveals heterogenous subsets and diverse TCR usage within SARS-CoV-2 reactive CD4+ T cells


1257

1258
1259 (A) UMAP showing 14,053 CD4+ T cells from CD25+CD134+ sorted cells from Ab high subjects
1260 split into 4 conditions: ex vivo memory; nucleoprotein (NP); Spike; and RBD. (B) Dot plot showing
1261 average expression of lineage genes and percentage of cellular expression within each cluster. (C)
1262 Enrichment of Treg populations in SARS-CoV-2-specific CD4 in addition to central/transition memory
1263 and cytotoxic subsets. (D) Diversity of TCR alpha and (E) TCR beta chain in all 4 conditions. Few
1264 select TCRa/b enriched in stimulated conditions compared to ex vivo memory expressed as log odds
1265 ratio with adjusted p values including Bonferroni correction. (F) Circos plots showing little transition
1266 of cell types between ex vivo memory and stimulated conditions.

1267

RBD-specific memory CD4 T cells


1268 Figure 7



1269 **Figure 7 – Proliferative clonotypes are enriched within Tregs and cytotoxic subsets**
 1270 Bulk TCR sequencing of CD4s T cells from Ab high subjects that proliferated for 5 days following stimulation with
 1271 SARS-CoV-2 peptide pools were matched with 10x single-cell TCRs to examine enriched clonotypes. (A) UMAP
 1272 clonotypes that were enriched following proliferation and matched to 10x TCRs and split into 4 conditions: ex vivo
 1273 memory, nucleoprotein (NP), Spike and RBD. (B) Proliferative CD4 clones were highly enriched with activated
 1274 GTR+ Tregs and cytotoxic clusters. (C) Abundance of unique single clonotypes with few expanded clonotypes
 1275 within stimulated conditions. (D) Minimal shared TCR clonotypes within stimulated conditions compared to ex vivo
 1276 memory. Fishers exact test with Bonferroni's corrected p values shown for log odd ratios.

RBD-specific memory CD4 T cells

1277 Figure 8



1278

1279 **Figure 8- Vaccination induces RBD-specific CD4 T cells in Ab low subjects**

1280 (A) Significant increase in RBD-specific CD4+ T cells following vaccination in Ab low group. (B) No

1281 difference in CD8 response in both groups post-vaccination. (C) Increase in antibodies following two

1282 doses of SARS-CoV-2 vaccination that neutralized both ancestral and delta viruses in Ab low and Ab

1283 high groups. (D) Positive correlation between RBD- specific CD4+ T cells and neutralising antibody

1284 titres post second dose of vaccination. Data shown as medians with interquartile ranges. Two-tailed p

1285 values < 0.05 were considered significant ($* < 0.05$, $** < 0.01$, $*** < 0.001$. Mann-Whitney T tests were

1286 used for unpaired groups. Pearson's rho was used for correlations and adjusted p values shown.

1287

1288

1289

1290

1291

1292

1293

1294

RBD-specific memory CD4 T cells

1295 **Supplementary Figures**

1296

Characteristics	ADAPT Cohort				
	Recombinant RBD 3 month OX40 screen	Antibody Low Convalescent	Antibody Low Vaccinated	Antibody High Convalescent	Antibody High Vaccinated
n	25	12	14	12	20
Mean age (y)	42 ± 10.8	47 ± 14.3	54 ± 17.9	54 ± 16.1	59 ± 13.8
Male gender, n (%)	12 (48%)	6 (50%)	9 (64%)	12 (100%)	12 (60%)
Ethnicity (n, %-total)					
- African American	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
- Asian	2 (8%)	0 (0%)	1 (7%)	0 (0%)	0 (0%)
- Caucasian	19 (76%)	10 (83%)	13 (93%)	12 (100%)	20 (100%)
- Hispanic	2 (8%)	2 (17%)	0 (0%)	0 (0%)	0 (0%)
- Others	2 (8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Median Days post infection					
3 months (FU3)	76 ± 18	74.5 ± 15	68 ± 19	62.5 ± 14	46.5 ± 25
8 months (FU5)	228 ± 60	228 ± 75	250 ± 30	226.5 ± 24	244 ± 69
Vaccination 2nd dose			528 ± 26		479 ± 87
Severity (n, %-total)					
- Mild	9 (36%)	6 (50%)	6 (42.85%)	2 (16.7%)	9 (45%)
- Moderate	16 (64%)	6 (50%)	6 (42.85%)	7 (58.3%)	8 (40%)
- Severe	0 (0%)	0 (0%)	2 (14.3%)	3 (25%)	3 (15%)

1297

1298

1299 **Supplementary Table 1- ADAPT study patient characteristics.** Age, gender, ethnicity, severity, and medi
 1300 neutralisation titre at month 3.

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

RBD-specific memory CD4 T cells

#	Peptide	Amino acid sequence
1	SN1	NNATNVV IKV CEFQF
2	SN2	CTFEYVSQPFLMDLE
3	SN3	TRFQTLALHRSYLT
4	SN4	LLALHRSYLT PGDSS
5	SN5	SVASQSI IAYTMSLG
6	SN6	SIIAYTMSLGAENSV
7	SN7	NLLLQYGSFCTQLNR
8	SN8	TQLNRALTGIAVEQD
9	SN9	NFSQILPDPSPKSKR
10	SN10	KPSKRSFIEDLLFNK
11	SN11	SFIEDLLFNKVTLAD
12	SN12	TDEMIAQYTSALLAG
13	SN13	AQALNTLVKQLSSNF
14	SN14	VQIDRLITGR LQSLQ
15	SN15	SLLVNNATNVV IKV
16	SN16	CEFQFCNDPFLGVYY
17	SN17	IGINITRFQTLALH
18	SN18	FTVEKGIYQTSNFRV
19	SN19	AYSNNSIAIPTNFTI
20	SN20	VFAQVKQIYKTPPIK
21	SN21	CAQFNGLTVLPPLL
22	SN22	AQYTSALLAGTITSG
23	SN23	WTFGAGALQIPFAM
24	SN24	GAISSVLNDILSRDL
25	SN25	APHGVVFLHVTVYPA
26	SN26	ELDKYFKNHTSPDVD
27	SN27	GINASVVNIQKEIDR
28	SN28	LNEVAKNLNESLIDL
29	SN29	YEQYIKWPWYIWLGF
30	SR1	GIYQTSNFRVQPTES
31	SR2	SNFRVQPTESIVRFP
32	SR3	QPTESIVRFPNITNL
33	SR4	IVRFPNITNLCPFGE
34	SR5	CPFGEVFNATRFASV
35	SR6	VFNATRFASVYAWN R
36	SR7	YAWNRRKRISNCVADY
37	SR8	GVSPTKLNDLCFTNV
38	SR9	GKIADYNYKLPDDFT
39	SR10	YNYKLPDDFTGCVIA
40	SR11	GCVIAWNSNNLDSKV
41	SR12	GGNYNYLYR LFRKSN
42	SR13	YLYR LFRKSNLKPFE
43	SR14	FNCYFPLQSYGFQPT
44	NP1	MSDNGPQNQRNAPRITF
45	NP2	NQRNAPRITFGGPSDSTG
46	NP3	DDQIGYYRRATRRIR
47	NP4	MKDLSPRWYFYLL
48	NP5	LSPRWYFYLLGTGPEAGL
49	NP6	LLESELVIGAVILRGHLR
50	NP7	DAALALLLDRLNQL
51	NP8	LLLLDRLNQLESKMS
52	NP9	AFFGMSRIGMEVTPSGTW
53	NP10	GMEVTPSGTWLTYTGAIK
54	NP11	PSGTWLTGTGAIKLD
55	NP12	TWLTGTGAIKLDKDPNF
56	NP13	PNFKDQVILLNKHIDAYK
57	NP14	LLNKHIDAYKTFPPTPEK


1327
1328
1329

Supplementary Table 2. Peptides. SN (spike), SR (RBD), NP (Nucleocapsid protein).


RBD-specific memory CD4 T cells

Supplementary Figure 1

1 A \



1B)



Supplementary Figure 1- T cell proliferation and phenotyping.


- (A) Proliferated cells at day 7 in response to antigen stimulation in Q1 CD25+CellTraceViolet-
 (B) Gating strategy of proliferated T cells using transcription factors and activation markers.

1330
 1331
 1332
 1333
 1334
 1335
 1336

RBD-specific memory CD4 T cells

Supplementary Figure 2

1A)




Supplementary Figure 2- CD39+ antigen-specific Treg responses.

(A) No difference was observed in CD39+ antigen-specific Tregs (CD25+CD134+CD4+) following stimulated with flu or SARS-CoV-2 peptide pools.


RBD-specific memory CD4 T cells

Supplementary Figure 3



2B)

Purity Check




Supplementary Figure 3- Cell sorting for single-cell transcriptomics.

(A) Representative dot of 1 participant shown following 48hr stimulation with SAR-CoV-2 peptide pools, with SEB as a positive control. Antigen-specific CD4+ T cells were bulk sorted from Q2 (CD25+CD134+) on the BD Aria III. (B) CD45RO+ ex vivo (unstimulated) memory CD4+ T cells were also bulk sorted for 10X sequencing. A purity of >99% was achieved for all samples.

RBD-specific memory CD4 T cells

Supplementary Figure 4



Supplementary Figure 4- Diversity of SARS-CoV-2 specific TCR clonotypes.
(A) Slightly lower Shannon's entropy scores for spike, RBD and NP compared to ex vivo memory. **(B)** Circos plot showing high diversity of TCR $\alpha\beta$ usage in all 4 conditions.